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2 List of abbreviations 
BCVA Best corrected visual acuity 
BM Bruch’s membrane 
CCD Charge-coupled device 
CFP Color fundus photography 
CRT Central retinal thickness 
CRVO Central retinal vein occlusion 
CSME Clinically significant macular edema 
DM Diabetes mellitus 
DME Diabetic macular edema 
DR Diabetic retinopathy 
DRCR.net Diabetic Retinopathy Clinical Research Network 
DRS Diabetic retinopathy study 
ELM External limiting membrane 
ETDRS Early treatment diabetic retinopathy study 
FA Fluorescein angiography 
FAF Fundus autofluorescence 
GCL Ganglion cell layer 
GLD Greatest linear diameter 
ILM Internal limiting membrane 
INL Inner nuclear layer 
IPL Inner plexiform layer 
IR Infrared 
IRMA Intraretinal microvascular abnormalities 
IS/OS Inner segment / outer segment * 
LogMAR Logarithm of the minimal angle of resolution 
Nd:YAG Neodymium-doped yttrium aluminum garnet 
NPDR Non-proliferative diabetic retinopathy 
OCT Optical coherence tomography 
OCTA Optical coherence tomography angiography 





OPL Outer plexiform layer 
PASCAL Pattern scanning automated laser 
PDR Proliferative diabetic retinopathy 
PRL Photoreceptor layer* 
PRP Panretinal photocoagulation 
RCT Randomized clinical trial 
RF Red free 
RNFL Retinal nerve fiber layer 
ROI Region of interest 
RPE Retinal pigment epithelium 
SD Standard deviation 
SD-OCT Spectral-domain optical coherence tomography 
SS-OCT Swept-source optical coherence tomography 
SLD Super luminescent diode 
TRP Thickest retinal position 
VA Visual acuity 
VEGF Vascular endothelial growth factor 









3.1 Laser therapy 
3.1.1 The physics of laser 
The word laser is an acronym for Light Amplification by Stimulated Emission of 
Radiation.1 The first publications mentioning an amplification chamber resulting with the 
emission of electromagnetic waves (microwaves) were published in the late 1940s 
simultaneously by two groups, Townes and Schawlow in the USA, and Prokhorov and 
Basov in the Soviet Union.2–4 Later the American group of physicists continued their 
experiments with amplification cavities to produce infrared and visible light. The diligent 
work of both groups has paid off as they were jointly awarded with the Physics Nobel 
Prize in 1964 and in 1981. The first description of a ruby solid state red light emitting 
laser was made by Maiman in his 1960 publication in Nature.5 The development of 
different laser “masters” has picked up pace in the following decades, and many of these 
laser types are still in use, such as gallium-arsenide phosphide laser diode in 1962 which 
is used in LEDs, CD and DVD players.6 Carbon dioxide laser and the neodymium-doped 
yttrium aluminum garnet (Nd:YAG) laser were both published in 1964 and are both used 
in medicine for surgery and the later used in ophthalmology and dermatology for multiple 
indications. 
The theoretical principals of lasers were described by Einstein in 1917, based on the 
quantum theory of Bohr and the hypothesis of de Broglie that light has a dual nature of 
wave and particle.7 In Bohr’s theory every material has a ground state energy. If this 
material is influenced by an external energy i.e. light, material can absorb energy and its 
molecules enter in an excited state. Usually after a short period of time these molecules 
return in to their ground state, and during this they emit a photon with the same energy as 
the energy difference between the molecules excited and ground states. This process is 
called a spontaneous emission (b). In Einstein’s hypothesis if a molecule in an excited 
state is irradiated by a photon it can force a transition to ground state, and the resulting 
excited photon will have the same energy, the same direction and the same phase as the 





Figure 1.: Changes in quantum systems after an interaction with electromagnetic 
radiation. a) material absorbing the energy of a photon (E=hv (h Planck constant, v 
frequency)) moves from its ground state (E1) to an excited state (E2). b) spontaneous 
emission occurs after the lifetime of the excited material expires. The material returns to 
its original ground state, and a photon is emitted with the same energy as the difference 
between the excited and ground states of the material (E2- E1). c) Stimulated emission 
happens when a photon irradiates material already in excited state. During stimulated 
emission the material returns to its ground state, and in the mean while two photons with 
the same energy (E2- E1), same direction and same phase is emitted. 
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In general lasers work the following way: A cavity is filled with a material that can be 
excited with a so called pump (which can be a flash lamp or some electric discharge). The 
material than enters in a “population inversion” state, where more molecules/atoms are in 
excited state than in their ground state. The two ends of the cavity are closed with two 
mirrors. One of these mirrors is a semi-reflective mirror, so that a light beam can escape 
the cavity. Inside the cavity photons are emitted as the excited material returns to its 
ground state. These photons which are in different polarization circulate in all directions 
inside the cavity, causing more and more stimulated emissions. Coherent light with the 
same wavelength, phase and directions escapes the cavity through the aperture of the 









Figure 2.: Schematic drawing of a laser cavity or optical (open) resonator.1 
 
3.1.2 Laser properties and radiation parameters 
The properties of a laser light can be described by the same characteristics as any other 
light type or electromagnetic radiation. These characteristics are directionality, coherence 
monochromaticity and high brightness. Laser beams are very well collimated meaning 
that the spread of the beam stays very small even when projected over a long distance. 
This enables that high fluences can be achieved by laser beams compared to other light 
sources. The light waves in a laser beam are coherent meaning that they are in the exact 
same phase when they exit the optical resonator, and stays this way for an extended travel 
length. Most of the laser systems used generate a light beam with a very narrow 
wavelength. This property is called monochromaticity. Although some laser systems offer 
the possibility to change the wavelength produced such as tunable lasers, still the 
wavelength window of these devices is so narrow that they can still be called 
monochromatic. Finally, since lasers generate light with very high energy with high 
directionality they can achieve high brightness compared to other light sources. 
The main parameters a laser beam can be described are the following: wavelength, pulse 
width or duration, repetition frequency, pulse energy of or mean power (depending on 





Wavelength can vary on a broad spectrum from infrared through the visible spectrum to 
UV and X-ray, and is generally dependent on the laser medium used. The optimal type of 
laser system for a specific use is mainly affected by the absorption characteristics of the 
target medium. The wavelength of a laser depends on the photon energy generated by the 
laser medium when it re-enters its ground state. Thus it has to be taken in to account, that 
photons of different wavelengths carry a different amount of energy, and therefore cause 
different effects on the target medium. 
Regarding temporal characteristics, lasers can be divided in two groups: continuous lasers 
and pulsed lasers. A continuous laser emits a continuous beam of light as long as the laser 
medium is excited, whereas in pulsed laser the laser emits pulses of energy. There are 
three typical regimes how lasers can produce both continuous and pulsed light. Free-
running regime means that the amplification process in not blocked and radiation 
amplifies freely within the laser resonator as long as the pumping is active. Depending 
upon whether the pumping is continuous or in pulses the laser emitted will also be 
continuous or pulsed. Q-switched lasers have a special shutter inside the resonator that 
prevents oscillation. The laser medium is activated by pumping, and when it reaches 
certain energy the shutter is opened and a very intense pulse is generated with a duration 
in the range of nanoseconds. If the pumping is continuous, a train of pulses is generated 
as long as the pumping continues. This is called a quasi-continuous Q-switched regime. 
Mode-locked lasers work similarly to Q-switched, but here the shutter causes the coupling 
of the longitudinal modes in the resonator so that their phases are locked. The beam 
created by mode-locked lasers is also similar to those of a Q-switched, but the pulse 
duration is even shorter in the range of pico- or femtoseconds. 
Energy and power of a laser are the most important parameters steering what effect the 
laser beam will have on the tissue. Energy –measured in Joules (J)- is usually used to 
characterize radiation in pulsed lasers, and power (average output power measured in watt 
(W)) is used to characterize radiation in continuously running lasers. In medical 
application the most important parameter to describe a laser radiation is fluence or energy 
density. It describes the total sum of energy delivered to a specific area of tissue. It is 





3.1.3 Tissue laser interactions and their implications in ophthalmology 
Laser can induce a wide variety of reactions in human tissue ranging from photochemical 
changes to instant vaporization of the material. The qualities of laser that determine what 
happens with the irradiated tissue are wavelength, fluence and irradiation time. In general 
the higher the absorbed photon energy and the shorter the timespan the energy is delivered 
the more tissue disruption is generated.9 
3.1.3.1 Photochemical interaction 
Photochemical interactions are usually induced with light sources that emit light that is 
not absorbed by the target tissue itself, but the effect is mediated by an exogenous agent 
instead. To avoid tissue heating the exposure times are generally much longer (multiple 
minutes), and the irradiance is usually very low. Here the laser is only used to activate the 
exogenous material, and the tissue changes are mediated by this agent.10 The two 
modalities using photochemical interaction that are currently performed are 
photodynamic therapy and corneal crosslinking. In the prior verteporfin is administered 
intravenously, and then the region of interest is irradiated with a low energy continuous 
laser with 689 nm wavelength. There is no thermal reaction involved, but the 
photoactivation of verteporfin that binds to low density lipoprotein (LDL)-receptors 
found on the endothelial cells of choroidal vessels cause vasoocclusion of choroidal 
vessels in the irradiated area. Retinal vessels that lack LDL-receptors are spared.11 In 
corneal collagen crosslinking riboflavin is applied locally on the corneal surface (after 
abrasion), and is than irradiated with a low intensity (3mW/cm2) UVA light for 30 
minutes. It has been shown, that corneal collagen crosslinking is able to prevent 
progression of corneal ectatic diseases.12 
3.1.3.2 Photothermal interaction 
Photothermal interaction can cause a broad range of tissue alterations depending on the 
amount of heat generated. Such alterations range from minor changes in cell metabolism 
such as cytokine expression to apoptosis and necrosis of the cell. Chromophores such as 
water, hemoglobin, melanin, xanthophyll and other pigments absorb the light in tissues, 
and their absorption spectrum defines which wavelength of light is necessary for an 
optimal laser effect. The amount of tissue damage is defined by the amount of intracellular 





depending on exposure time as described by the Arrhenius integral. The most common 
form of photothermal laser interaction is retinal photocoagulation. 
Laser wavelength used for retinal photocoagulation varies between 488 and 694 nm 
(argon and ruby laser respectively), but most commonly frequency doubled Nd:YAG 
lasers or semiconductor lasers with 532 nm (green) or 577 nm (yellow) respectively are 
used. In this wavelength spectrum the two chromophores absorbing laser energy are 
hemoglobin and melanin in the retinal pigment epithelium (RPE) and in the choroid. 
During a laser pulse application heat is generated at the level of the RPE. Depending on 
the power and the pulse duration this access heat diffuses to the adjacent tissue in 360°. 
This phenomenon is called thermal blooming. When a laser pulse with 100 ms duration 
is applied to the retina, heat diffusion can reach up to 200 µm meaning not only that the 
tissue at the lateral edges of the lesion will be affected (and with that the effective lesion 
size will be larger) but also the inner retinal layers including the retinal nerve fiber layer 
(RNFL) will be affected causing more widespread damage as the size of the lesion 
alone.13 With the reduction of the pulse duration the amount of thermal blooming can be 
reduced, but to achieve the same visible threshold laser effect the laser energy has to be 
increased. After a certain reduction of the pulse duration unwanted photomechanical 
interactions might occur. 
3.1.3.3 Photomechanical interaction 
If a high energy laser with a very short exposition time (tens of ns) is applied on a tissue 
it causes a photoablation as the temperatures achieved are higher than the vaporization 
threshold. The gas bubbles created by the vaporization create small explosions that 
rupture nearby tissue with very high precision and only minimal tissue damage at the 
edges of the treatment zone. Photodisruption and dielectric breakdown happen when the 
pulse duration is even shorter (in the nanosecond-femtosecond region). If the energy is 
applied in such a short pulse plasma develops and mediates rapid explosive vaporization 
to the tissue. Photoablation is used in ophthalmology in laser mediated corneal surgery 
where nanosecond pulses of 193 nm wavelength laser irradiation causes extremely 
precise ablation of stromal tissue. With such short pulse duration the residual tissue 
damage is extremely low. Plasma mediated photodisruption is used to perform laser 





liquid medium causing tissue rupture. With pulse durations in the femtosecond range 
photodisruption is used to perform the precise dissection of the corneal stroma, lens 
capsule and crystalline lens during femtosecond assisted cornea and cataract surgery. 
3.1.4  The brief history of retinal photocoagulation 
Ophthalmology is an ideal field for the use of lasers both in the treatment and in the 
diagnosis of diseases, since the eye is mainly built by tissue with clear optical properties. 
The first description of “laser” coagulation of the retina was actually light 
photocoagulation developed by a German ophthalmologist Meyer-Schwickerath.14,15 He 
developed an elaborate conception on the roof of the Department of Ophthalmology in 
Hamburg-Eppendorf in the late 1940s to collect sunlight, and used a series of mirrors to 
bring the light ray in to the operating theater. Later in the 1950s he deployed a high 
pressure xenon arc lamp as light source, thus eliminating the need of direct sunlight.16 
The same year Meyer-Schwickerath failed with the first attempts of light coagulation, 
Kettesy the chair of the Department of Ophthalmology in Debrecen performed the first 
successful light coagulation in a patient with a retinal tear by having the patient look in 
to the sunlight.17 Among others retinal detachments and diabetic retinopathy were among 
the first diseases to be treated with light and photocoagulation.18–20 
The first truly “modern” concept of how to perform laser therapy in patients with 
proliferative diabetic retinopathy was described by Beetham et al in 1969.21 The first 
randomized clinical trial examining the beneficial effects of laser was the diabetic 
retinopathy study (DRS). The DRS study started in 1972 and showed that panretinal 
photocoagulation (PRP) reduced the risk of severe visual in loss in 4 years both in the 
severe nonproliferative (NPDR) as well as in the mild and high-risk proliferative diabetic 
retinopathy (PDR) groups, with achieving a 24% reduction in the latter group.22 The early 
treatment diabetic retinopathy study (ETDRS) was one of the most important landmark 
studies in diabetic retinopathy. It not just evaluated the effect of macular and panretinal 
laser treatment but also laid down the basis how we measure functional outcomes like 
visual acuity, how to analyze morphologic endpoints, and how to classify diabetic retinal 
disease.23,24 In respect of laser treatment the ETDRS study examined the effect of macular 
and panretinal laser therapy in patients without high risk characteristics. It showed that 





in patients with clinically significant macular edema with or without macular 
involvement.25 Regarding PRP showed that it is safe to defer treatment in patients with 
severe NPDR or non-high-risk PDR until high-risk characteristics are seen.26 In the 1980s 
laser therapy was examined in the indications for all major retinal diseases. The branch 
vein occlusion study showed, that in patients with macular edema due to branch retinal 
vein occlusion macular grid photocoagulation treatment resulted in better visual outcomes 
(65% vs 37% of eyes with 2 line VA improvement laser vs sham respectively) than 
observation. Furthermore the study showed that sectorial PRP reduced the risk of severe 
VA loss in patients with retinal or iris neovascularization.27,28 The central vein occlusion 
study however showed that grid photocoagulation provided no benefit to patients with 
macular edema due to central retinal vein occlusion, but prompt panretinal 
photocoagulation was necessary and beneficious if neovascularization on the retina or iris 
occurred.29 In age-related macular degeneration the macular photocoagulation study laid 
out the basis of performing laser therapy in patients with choroidal neovascularisations.30 
3.1.5 Current challenges of laser therapy in diabetic retinal disease 
Since the results of the DRS and ETDRS studies were published laser photocoagulation 
was the only approved and effective therapy for patients with diabetic macular edema and 
proliferative diabetic retinopathy.31 This changed with the advent of novel 
pharmacological therapeutics in the late 2000s and early 2010s. Multicenter randomized 
clinical trials like the Ride/Rise, Vivid/Vista and Restore studies showed that intravitreal 
anti-vascular endothelial growth factor (anti-VEGF) therapy is more effective in 
improving visual acuity, reducing macular thickness and preventing sever visual loss than 
macular laser therapy in patients with diabetic macular edema (DME).32–34 
The Diabetic Retinopathy Clinical Research Network (DRCR.net) conducted multiple 
studies regarding diabetic eye disease. In Protocol I they compared the efficacy of 
ranibizumab with prompt (at time of initiation of treatment) and deferred (≥24 weeks) 
focal/grid laser treatment. The 3-year results of the study suggested that focal/grid laser 
treatment at the initiation of intravitreal ranibizumab therapy was not better, and possibly 
worse for vision outcomes, than deferring laser treatment for ≥24 weeks in eyes with 





prompt or deferred laser was more effective through 2 years compared with prompt laser 
alone for the treatment of DME involving the central macula.  
Another landmark study from the DRCR.net -Protocol S- compared the effectiveness of 
panretinal photocoagulation vs. anti-VEGF therapy for proliferative diabetic 
retinopathy.35,36 In this randomized, multicenter, noninferiority trial, 394 eyes of 305 
adults with PDR were randomized to receive either PRP or anti-VEGF therapy (pro re 
nata). Eyes in both groups were allowed ranibizumab if DME was present. The study 
showed that rates of active neovascularization or rates of regression of neovascularization 
were similar between the two groups. Ranibizumab was not inferior to PRP in terms of 
visual acuity outcomes at 2 years (+2.8 letters vs. +0.2 letters respectively P<0.001). In 
the ranibizumab group there was less mean reduction in peripheral visual field (-23 dB 
vs. -422 dB; P<0.001) than with PRP treatment. The rates for vitrectomy (15% vs. 4%; 
P<0.001), and DME development (28% vs. 9%; P<0.001) was more frequent in the PRP 
group than in the ranibizumab group. 
PRP has known side effects, most of all loss of visual field, worsening of night vision, 
but also reduced color vision and reduced contrast sensitivity.37 Furthermore small case 
series reported loss of accommodation, and atonic pupils following PRP:38,39 Despite 
these known side effects the DRCR.net study and its post-hoc analysis concluded, that 
although anti-VEGF therapy for the treatment of PDR is as good as panretinal 
photocoagulation, PRP is still a viable therapy option for this condition due to its long 
lasting effect, cost effectiveness, and less time burden due to less follow-ups on the 
patients and the health care system.36,40 
Current guidelines rely on the clinician’s decision on how they manage PDR. Anti-VEGF 
therapy might be a good option for patients with simultaneous DME, while patients with 
historically bad compliance might benefit more from PRP.41,42 Data shows patients with 
poor compliance treated with anti-VEGF monotherapy often return after falling out of 
regular checkups with advanced PDR complications.43  
In order to minimize side effects associated to PRP and to maximize patient and physician 
comfort a number of novel technological advances have been introduced. One of these 





duration. Animal model studies showed that with reduction of the laser pulse duration the 
acute damage of the inner retinal layers can be significantly reduced (Figure 3).13,44 
Furthermore when only the outer layers of the retina are acutely damaged with shorter 
pulse durations a considerable amount of regeneration and remodeling was observed in 
the retina. The continuity of the RPE monolayer was restored through RPE migration and 
proliferation within 1 week compared with damage of longer-duration pulses of 100 ms.45 
The damage zone in the photoreceptor layer is initially filled with glial tissue, but over 
time, the photoreceptors from the adjacent retina shift into the damage zone, thereby 
reducing its size. With lesion size of 200 mm and below, and with no damage to the inner 
retinal layers, photoreceptors can completely refill the damage zone and rewire to local 
bipolar cells over time, thereby restoring retinal structure and function and avoiding the 
extensive glial scarring and neuronal loss associated with longer-duration retinal burns.45 
Another advantage of such a laser system, that it allows the subsequent placement of 
multiple laser burns in predefined pattern within a short period of time in order to reduce 
the time needed to perform the laser procedure. 
 
 
Figure 3.: The acute phase pf A) 10 and B) 100ms laser burns. A) Damage after 10ms 
laser pulse duration is limited to the RPE and photoreceptors. The inner retinal layers are 
intact. B) There is a considerable amount of damage to the choroid as well as the inner 
retinal layers in the acute phase. 44 
 
Creating funduscopically and/or instrumentally non-visible subthreshold laser burns 
using micropulsed diode lasers is another method to reduce laser side effects. In 
micropulsed laser the laser pule is not applied in a continuous wave, but in trains of laser 





off-times. This fractioning of the laser energy enables better heat diffusion in the tissue, 
and therefore the RPE is treated with a sublethal effect.46 The hypothetical endpoint of 
subthreshold micropulsed laser therapy is not the destruction of the RPE but its 
modulation, to change its cytokine expression.47,48 Early retrospective and prospective 
studies with small patient numbers showed promising results with micropulse laser in the 
treatment of DME and in PDR.49–53 Randomized clinical trials to confirm these findings 
are currently under way.54 In other diseases such as central serous chorioretinopathy 
subthreshold micropulse laser was found inferior to current standard of care (halved 
fluence PDT), although some authors question the results due to the laser protocol 
used.55,56 
 Navigated lasers use fundus tracking technology in order to find regions of interests, and 
deliver laser radiation to the exact location selected by the operator. Pre-treatment 
planning of the treatment is possible either from fundus photography or even from 
fluorescein angiography (FA) images. FA images captured can be registered to the real-
time fundus image, and regions of interest such as microaneurysms can be treated even if 
they are not visible on fundus examination. Navigated lasers promise higher accuracy 
when aiming at small lesions due to the eye movement tracking, and also higher safety as 
predefined safety zones are constantly monitored, so that inadvertent treatment of these 
is not possible.57 Large randomized studies like the Restore trial and Protocol I did not 
show benefit in combining anti-VEGF therapy with conventional ETDRS macular laser 
therapy for achieving better visual acuity or reducing the number of injections.33,58 Some 
authors suggested, that the heterogeneity in the quality of how macular laser was 
performed limited the additional beneficial effect. A small randomized prospective study 
comparing anti-VEGF therapy with either navigated laser or conventional laser did not 
find a statistically significant difference in the number injections nor in VA improvement 
and central retinal thickness loss after 12 months.59 Another study compared anti-VEGF 
in monthly versus treat and extend regiment versus treat and extend anti-VEGF plus 
navigated focal laser therapy. At 2 years the study found no significant difference between 
anti-VEGF alone vs. navigated laser plus anti-VEGF in terms of VA gain, central retinal 





In summary novel laser technologies may provide potential benefits for the patients, but 
these have to be confirmed in randomized clinical trials. 
3.2 Optical Coherence Tomography 
Optical coherence tomography (OCT) is a novel and emerging imaging modality in 
medicine, and in its short existence of roughly 30 years became a major diagnostic tool 
in everyday clinical life especially in ophthalmology. The basic functionality of OCT is 
somewhat similar to ultrasound, but instead of sound it uses light to penetrate and 
backscatter from biologic tissues. It does not possess the high penetrance of ultrasound, 
but has a much higher resolution than that. Although OCT had a slow start, and the first 
commercial instruments were difficult to use and were not widely used and accepted, as 
soon as more practicable instruments were presented they became widely popular in the 
field of ophthalmology.61 Today OCT is among the most commonly performed ocular 
examination, and became standard of care in the diagnosis and management of retinal 
diseases. The fact that it is noninvasive, quick, and extremely reproducible it became the 
ideal diagnostic tool to monitor patients treated with intravitreal injections, where controls 
are frequently necessary, and treatment decisions have to be made based on only slight 
changes. Further developments of OCT technology such as OCT angiography (OCTA) 
promise to aid an even broader spectrum of clinical decisions with valuable information. 
The physical background of optical coherence tomography, low-coherent of white light 
interferometry was first described by Sir Isaac Newton. The fist instrument that used 
interferometry to measure distance was constructed by Michelson who used it to measure 
the diameter of stars in 1921.62 A schematic drawing and description of a Michelson 
interferometer is shown in Figure 4. In 1988 Fercher et al. reported the first biological 
(and ophthalmological) use of interferometry, when they used it to measured axial length 
of eyes.63 This sort of interferometry is still used, and became standard of care in modern 








Figure 4.: Schematic drawing of a Michelson interferometer. A light source emits a low 
coherent light passes through a beam splitter (half-silvered mirror). One light beam is 
projected on a mirror at a known distance (reference arm). The other beam is measured 
at the test object with unknown distance. Both reflected beams pass through the beam 
splitter again and the created interference is captured by a detector. (Authors own image) 
 
The first ever OCT image was published in 1991 by Huang et al.64 These early images 
demonstrated that OCT image although not completely identical, showed very high 
resemblance to histological sections (Figure 5). The development of OCT technology 
progressed rapidly, the first in vivo images were published by Fercher and Swanson in 
1993, and the first commercially available OCT device was introduced in 1996 by Carl 
Zeiss Meditec.65,66 Although the first two generations of OCT devices, the OCT1 and 
OCT2 sold only a few hundred pieces, the introduction of the StratusOCT in 2001 with 
its enhanced handling and faster scanning times brought a breakthrough in OCT 
technology.61 In Hungary a fair amount of publications were published with early 







Figure 5.: Right: The first ever OCT image published by James Fujimoto’s lab at the 
Massachusetts Institute of Technology of an ex vivo human retina and optic nerve head. 
The axial resolution of the scan is 15 μm. Left: the corresponding histologic image.64 
 
The most important parameters in OCT imaging are: axial image resolution to enable the 
detailed visualization of retinal layer architecture. Axial resolution is determined by the 
wavelength and bandwidth of the light source. Transverse resolution is determined by the 
spot size of the focused light beam. The smaller spot size (larger numerical aperture) the 
finer the transverse resolution will be. On the other hand the smaller the spot size is the 
lesser the depth of field will be. In ocular media transverse resolution is mainly limited 
by optical aberrations of the eye. The advent of adaptive optics technologies will help 
overcome these limitations.70 Data acquisition time is also an important factor, and is 
something that developed rapidly in the last decade with the introduction of Fourier 
domain detection, high speed detectors and swept light sources. Detection sensitivity 
determines the ease to capture a good-quality OCT scan and together with penetration 
depth is dependent on the wavelength of the light source, but also have an inverse 
relationship with acquisition speed. 
3.2.1 Time-Domain OCT technology  
The first three generations of OCTs were based on time-domain detection (TD-OCT) 
technology. In order to map the depth of different reflexes from the detector this 
technology uses a moving mirror in the reference arm of the interferometer. This moving 
mirror moves between its endpoints once for every A-scan performed (Figure 6). As light 
source a super luminescent diode (SLD) with a wavelength near 800 nm with a bandwidth 





axial resolution was enough to image most of the retinal layers, but the outermost retinal 
layers and the retinal pigment epithelium (RPE) were only displayed as a single 
hyperreflective band (Figure 7.). Research instruments with broad bandwidth titanium-
sapphire laser were able to achieve approximately 3 µm axial resolution.71,72 The main 
limitation of TD-OCT technology was acquisition speed. The StratusOCT the fastest 
commercially available TD-OCT had 400 A-scans per second acquisition speed.61 
Although this was enough to capture detailed images of the macula it was prone to image 
artefacts due to eye movements that would limit interpretation. Furthermore due to the 
slow acquisition speed it could only perform line scans, and radial patterns scans. Retinal 
thickness measurements that were introduced to aid clinical decision making relied on the 
segmentation of the innermost border of the retina the vitreoretinal interface, and the 
outermost part of the retina the inner border of the hyperreflective RPE band. Since large 
areas of the retina were not scanned between the radial scans these thickness values were 
interpolated. Thus segmentation errors in one of the line scans would affect a large area 







Figure 6.: Schematic drawing of a time domain optical coherence tomography. (TD-
OCT) The reference mirror moves back to forth at every A-scan captured. Once an A-
scan was captured the scanning mirror moves to the next retinal location to capture the 
next A-scan. (Authors own figure) 
 
 
Figure 7.: Layers of the retina. A) Image captured with an SD-OCT device. B) Image 
captured with a TD-OCT device. ILM: internal limiting membrane, RNFL: retinal nerve 
fiber layer, GCL: ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, 
OPL: outer plexiform layer, ONL: outer nuclear layer, ELM: external limiting membrane, 
IS/OS: inner segment / outer segment junction, IZ: interdigitation zone, RPE: retinal 
pigment epithelium, HRPEB: hyperreflective RPE band. (Authors own figure) 
 
3.2.2 Spectral-Domain OCT Technology 
In conclusion the greatest drawback of TD-OCT technology was slow acquisition speed. 
The answer to that came when a mathematical formula the Fourier transformation was 
applied in OCT technology. Instead of measuring optical echo signals sequentially as in 
time domain detection, Fourier/spectral domain OCT measure the entire optical echo 
signal simultaneously by using a spectrometer and a high-speed charge-coupled device 
(CCD) camera to detect interferometric information for the depth-resolved reflectivity 







Figure 8.: Schematic drawing of an SD-OCT device. In comparison to TD-OCT (Figure 
6) the mirror in the reference arm is stationary. The reflected beam of the measurement 
and reference arm reaches the CCD camera through a diffraction grating. (Authors own 
figure) 
 
Since a constantly moving reference mirror is not necessary, image acquisition is faster, 
and only limited by the speed of the CCD camera. Thus commercially available SD-OCT 
devices can achieve acquisition speeds ranging from 20 000 to 100 000 A-scan per 
second. Increased speed has many advantages, first of all much more B-scans can be 
captured in the same time period as with TD-OCTs, thus new volumetric scan patterns 
imaging the complete macular or even the complete posterior pole became feasible. 
Motion artefacts can still occur between individual B-scans, but not within B-scans, and 
this decreases the chances of false or missed diagnosis due to artefacts.74 This enables 
more precise thickness measurement as well. Secondly, higher acquisition speed together 
with advanced eye motion tracking technologies enable the capturing of multiple B-scans 
at the exact same retinal location. This on one hand makes image averaging to enhance 
signal-to-noise ration possible, and on the other hand enables the comparison of B-scans 
repeated within a fraction of time, and extraction of pixels with changes in reflectance or 
phase change between the two scans. This technology is called OCT angiography 





speed is that even with more B-scans to be taken the examination is still shorter than with 
TD-OCT, thus making the examination easier for both the patient and the examiner. 
Of course there are also drawbacks of SD-OCT technology. The greatest drawback is the 
reduced depth measurement range. In SD-OCT technology the number of axial pixels in 
an A-scan is limited by the number of pixels in the CCD camera of the device. Fourier 
transformations halves the number of the axial pixels, meaning that there is a tradeoff 
between axial resolution and depth range. Due to limitations in current spectrometer 
resolution and pixel crosstalk effect in CCD cameras there is also a significant loss of 
sensitivity with increasing depth range. Post-processing algorithms can help reduce this, 
but depth range remains still an issue with SD-OCT technology.75 
3.2.3 Swept-source optical coherence tomography 
Swept-source OCT (SS-OCT) takes another approach to Fourier transformation. Instead 
of using a broad spectrum SLD light source and using a spectrometer to extract spectral 
information, SS-OCTs use a tunable laser light source with a narrow band that sweeps 
over the optical bandwidth and interferometric information is detected by a single 
photodetector.76 This eliminates the speed limit that SD-OCTs have with currently 
available CCD technologies, and results in a much simpler system setup (Figure 9). Thus 
SS-OCT systems can achieve even higher acquisition speeds than SD-OCTs with 
commercial devices already in the 200 000 A-scans per second range, and research 
devices in the MHz  range.77 Higher speeds allow for even higher quality and even wider 
fields of view than before. Furthermore most SS-OCT devices use 1050 nm wavelength 
lasers. Compared to the most commonly used 800-820 nm used in SD-OCT SLDs this 
wavelength penetrates better and is less attenuated by optical opacities or the RPE, and 
has an enhanced depth range. As a downside axial resolution is somewhat less than what 
is achievable with 800 nm SD-OCTs. Another more practical downside of SS-OCTs is 







Figure 9.: Schematic drawing of a swept-source OCT device. The light source here is a 
laser sweeping through the optical bandwidth with extremely high speed. This eliminates 
the need of a spectrometer, and a single photometer is used as a detector. (Authors own 
figure) 
3.2.4 OCT angiography 
One of the most exciting new innovation in OCT technology was the introduction of OCT 
angiography.78,79 On the basis of SD and SS-OCT technology OCTA enables the indirect 
visualization of retinal and choroidal vessels, and that in a non-invasive and three 
dimensional way. As briefly mentioned earlier in OCTA two OCT B-scans are taken from 
the same exact retinal location with only a few millisecond delay in-between. The only 
movement to be expected in the retinal tissue in this short time period is the flow of blood 
cells within retinal (and choroidal) vessels. The two most commonly used method to 
visualize flow are amplitude decorrelation and phase variance detection.78,79 In the 
former, the amplitude change between subsequent B-scans is analysed, in phase variance 
the change in the phase of the light reflected from moving objects in respect to the 
emitting light source are analysed in the repeated B-scans. Proprietary algorithms 
developed by different OCT companies are based on these two methods. 
On OCTA flow information is usually presented by highlighting pixels where movement 





angiography (FA) is that the flow information on OCTA is 3 dimensional and with 
appropriate layer segmentation the different vascular plexuses of the retina such as the 
superficial, middle and deep capillary plexus can be separated and presented individually 
in a 2D en-face projection image that is very similar to the images ophthalmologist are 
used to when examining FA images (Figure 10). These deeper plexuses are not visible on 
FA, so with OCTA new information can be gathered about the retinal circulation.80–82 
Another major difference between FA on OCTA that since no dye is used, there is no dye 
leakage to be seen. This has the advantage, that there is no masking effect from the 
leakage, but on the other hand the source of fluid accumulation cannot be so easily 
detected as in FA. This information can be indirectly gathered by analysing the normal 
reflectance OCT images, but there is still a lot to learn about the correct interpretation of 
OCTA images. 
OCTA is a very promising modality as it is quick to perform, non-invasive, and as such 
repeating examination frequently is less burden to the patients as conventional FA. 
Unfortunately, current OCTA technology is very prone to artefacts and this limits the 
interpretation of the images greatly. The most commonly seen artefacts are motion, 
shadowing and projection artefacts (Figure 10). Although all OCTA devices are equipped 
with an eye tracking hardware or software algorithm, bulk eye movement can still present 
in motion artefacts. They increase background noise and reduce the signal to noise ratio 
necessary to detect flow. Shadowing is also a known artefact in SD- and SS-OCT 
technology. If a lesion in the inner layers of the retina has a very high reflectivity the light 
that passes through it will not be enough to reflect the signal of layers beneath this object 
back to the detector. This will result in a darker appearing area (shadow) beneath the 
reflective lesion. In OCTA even a minor shadowing –where reflectance information of 
the outer layers can still be gathered- can reduce the signal enough that no flow 
information can be extracted. Such a lack of flow information can be mistaken for real 
lack of flow. The most dreaded and most commonly misinterpreted artefacts are 
projection artefacts. Since retinal vessels cast shadows to the deeper layers (especially the 
highly reflective RPE layer) the flow movements in the retinal vessels will cause the same 
amplitude and phase changes in their shadows, and will be picked up by the algorithms 
as flow in the deeper layers. Thus flow information of the superficial layers will be 





reduce projection artefacts. Simpler options are to simply subtract flow information of 
the inner layers form outer layers. This comes with a loss of information of the flow in 
the outer layers. More sophisticated algorithms are being developed and show promising 
results in making OCTA images more easily interpretable.83,84 
 
 
Figure 10.: OCT angiography of a patient with central retinal vein occlusion captured 
with an SS-OCTA system. A) En-face projection of the superficial capillary plexus. The 
foveal avascular zone is irregular, the perifoveal capillaries are dilated and intercapillary 
spaces are widened. Nasal and temporal to the fovea confluent areas without flow i.e. 
ischemic areas. B) En-face projection of the deep capillary plexus, the perifoveal capillary 
bed is severely damaged, the ischemic areas seen in the superficial plexus are even more 
pronounced. Dark round areas in the center represent cystic spaces. Large and medium 
vessels seen in A) are projected to the deeper layer. C) B-scan through the foveal center 
cystoid macular edema with disorganisation of the inner layers in the center, and marked 
thinning and loss of inner retinal layers nasally and temporally. Red dots represent flow 






3.3 Diabetic retinal changes 
3.3.1 Diabetes mellitus 
Diabetes mellitus (DM) is a heterogenic group of metabolic diseases affecting the body’s 
carbohydrate, fat and protein metabolism.85 There are two main forms of diabetes. Type 
1 is characterized by the cellular mediated autoimmune inflammation and destruction of 
the insulin secreting β-cells of the pancreas. This form was formally known as juvenile-
onset DM or insulin-dependent DM as in most of the cases (although by far not in all 
cases) the disease develops in younger patients, and they need insulin substitution for 
survival. Type 1 DM constitutes 5-10% of all diabetes cases.85 Type 2 DM is a group of 
diseases characterized by either increased insulin resistance or an insulin secretory defect 
combined with some degree of insulin resistance. In the past type 2 DM was referred to 
as noninsulin-dependent DM, as patient do not need insulin to survive, but still many 
patients with type 2 DM will need to take insulin to achieve good glycemic control. 
Obesity is a major risk factor for type 2 DM as it increases insulin resistance. Type 2 DM 
is by far the more common disease as it comprises 90-95% of all diabetes cases. 85 
A calculation based on epidemiological studies from 91 countries estimated a 6,4% 
prevalence of diabetes mellitus worldwide affecting 285 million adults in 2010. They 
predicted an increase of prevalence to 7,7% (affecting 439 million adults) by 2030, where 
the increase in prevalence in the developing countries will be 69% and in the developed 
countries around 20% in this time period.86 In the USA according to the 2017 report of 
the Centers for Disease Control and Prevention 9,4% of American adults (30,2 million) 
are affected with DM and an additional 79 million have impaired fasting blood glucose 
levels.87 
In summary the number of patients with diabetes is constantly and rapidly rising with the 
population growth of developing countries and the aging of western countries.88 Health 
care systems must prepare for the management of these patients especially their late 





3.3.2 Diabetic retinopathy 
Diabetic retinopathy (DR) is the most common ocular sequelae of diabetes mellitus, and 
one of the leading causes of blindness in the working age population worldwide.89–94 The 
prevalence of diabetic retinopathy worldwide is estimated to affect around 93 million 
adults and vision threatening diabetic retinopathy worldwide is estimated to affect around 
28 million adults with around 50% of these patients coming from the Asia-Pacific 
region.95,96 
The most important risk factor for the development of diabetic retinopathy is duration of 
diabetes. In the Wisconsin Epidemiologic Study found that the after 5, 10 and 15 years of 
type 1 diabetes 25%, 60% and 80% of patient will develop diabetic retinopathy 
respectively.97,98 In type 2 diabetes depending whether the patients required insulin to 
manage their diabetes 24% or 40% (no insulin, with insulin respectively) developed DR 
after 5 years, and 53% or 84% (no insulin, with insulin respectively) developed DR after 
19 years of DM duration.97 A study of 1433 young patient with DM showed, that diabetic 
retinopathy is more common and usually more severe in patients with type 1 DM than in 
type 2 DM (20% vs 4% respectively). In real life since there are much more patients with 
type 2 diabetes, most of the patients seen in the clinics with ocular complications are in 
fact type 2 DM patients.99 A recent study conducted in Hungary in 50 years and older 
population showed that the prevalence of DM was 20%, and in the patients with DM the 
prevalence of DR and/or diabetic maculopathy was 20.7%.100 
Regarding modifiable risk factors blood sugar, blood pressure and blood lipid levels seem 
to be the most important. The importance of glycemic control in the development of DR 
and especially on the severity of DR after development have been confirmed in multiple 
studies, and although blood pressure and blood lipid control is beneficial in diabetes 
mellitus its impact on diabetic retinopathy is still to be confirmed.101–104 
The most commonly accepted theory is that diabetic retinopathy is a microangiopathy 
caused by the hyperglycemia induced cellular changes in retinal capillaries leading to the 
formation of capillary occlusions and microaneurysms.105,106 There is growing evidence 
that parallel to these vascular changes, or even proceeding these there is a neurovascular 





Clinically diabetic retinopathy can be divided into two stages. Nonproliferative diabetic 
retinopathy (NPDR) is characterized by microaneurysms, intraretinal hemorrhages, 
venous dilatations and in later stages cotton wool spots, hard exudates, venous beading 
and intraretinal microvascular abnormalities (IRMA) (Figure 11).109  
 
 
Figure 11.: Wide-field fundus photography (CF) and fluorescein angiogram (FA) of a 
patient with moderate nonproliferative diabetic retinopathy (NPDR). CF shows numerous 
microaneurysms in the posterior pole and outside the vessel arcades, as well a multiple 
cotton wool spots and intraretinal hemorrhages. Signs of severe NPDR such as extensive 
intraretinal hemorrhages in 4 quadrants, venous beading in 2 or more quadrants or 
prominent intraretinal microvascular abnormalities (IRMA) are not seen. FA shows the 
extensive amount of microaneurysms and focal areas of capillary nonperfusions. 
 
Diabetic retinopathy progresses gradually with the increasing amount of retinal capillary 
occlusion. These occlusions promote the expression of various cytokines among them the 
most important VEGF. VEGF induces to vascular remodeling seen in the form of shunt 
capillary formations (i.e. IRMA), increased vascular permeability (i.e. diabetic macular 
edema formation), and the formation of new vessels either on the inner surface of the 
retina or in more severe cases in the anterior segment. Such neovascularization either on 
the optic nerve head, around retinal vessels or on the iris are the leading signs of a 







Figure 12.: Wide-field fundus photography (CF) and fluorescein angiogram (FA) of a 
patient with proliferative diabetic retinopathy (PDR). Neovascularizations elsewhere 
(NVE) are readily seen on CF as well as preretinal and intravitreal hemorrhages. The 
middle periphery is covered with pigmented panretinal photocoagulation (PRP) scars. 
Late phase FA shows even more leaking NVEs as well as ischemic areas already covered 
by the PRP. The macular area shows diffuse and focal leakage. 
 
3.3.3 Diabetic macular edema 
Diabetic macular edema is sequel of diabetic retinopathy, and can develop both in NPDR 
as well as PDR stages. It is characterized by the increased inflow of fluid, proteins and 
lipids from the retinal vasculature -due to increased vascular permeability- into the 
extracellular space of the retina. This causes thickening of the retina, formation of 
intraretinal cystoid spaces, subretinal fluid accumulation, and the formation of hard 
exudates (Figure 13). Although retinal thickening does not directly correlate to visual 
acuity it is still the main cause of visual impairment in patients with diabetic 
retinopathy.90,110  
Before the advent of OCT technology, DME was detected based on fundus examination 
(or fundus photography in clinical trials) aided by fluorescein angiography. The ETDRS 
study divided DME into clinically significant macular edema (CSME) and non-CSME 
based on the location and extent of the retinal thickening and hard exudates on fundus 
exam or fundus photography. OCT made the detection and quantification much simpler, 





symptoms. Randomized clinical trials (RCTs) in the OCT era usually define DME using 
central subfield thickness, and the presence of fluid compartments on OCT (Figure 13). 
 
 
Figure 13: Infrared image with retinal thickness heat map and OCT image of a patient 
with center involving DME. On the heat map warmer colours represent thicker retina. 
OCT shows intraretinal cystic spaces in the outer and inner nuclear layers (ONL and INL), 
subretinal fluid accumulation under the fovea, multiple hyperreflective foci at the apical 









Although in indications such as diabetic macular edema novel therapeutic approaches 
became the standard of care grid and focal laser therapies can still have their value in the 
armamentarium of therapies.31–33,42,111–114 In other indications like proliferative diabetic 
retinopathy retinal photocoagulation is still the preferred way of treatment due to its long 
lasting effect.35,36,115 Although the timely execution of laser therapy can save the patient 
from profound visual loss due to vitreous hemorrhage or tractional retinal detachment, it 
is well known, that panretinal laser photocoagulation has a number of side effects such as 
peripheral visual field loss, night blindness or central visual decrease.36,116 These side 
effects can have a major impact on the quality of life of patients with PDR, since many 
of these patients are still in the working age group, whose daily job and living might 
depend on their eyesight. 
Novel developments in laser technology showed promising results in animal models in 
reducing collateral damage when performing laser therapy.13,45 It is a well-known feature 
that laser scars grow with time, and cover larger and larger areas of the peripheral retina 
further reducing the already impaired peripheral retinal function. Furthermore animal 
model studies confirmed, that laser burns applied with standard laser pulse durations 
cause disruption of the RNFL causing further functional loss.13,44 It is imperative for the 
wellbeing of our patients to develop and apply the most beneficial therapeutic approach 
with the least amount of collateral damage. 
The aims of our research were the following: 
1. examine the in vivo effects of a short duration continuous thermal laser onto the 
human peripheral retina using optical coherence tomography 
2. examine the longitudinal healing process of laser burns, and quantify laser scar 
size changes over time 
3. examine the immediate in vivo morphologic changes after macular grid 
photocoagulation using a short duration continuous thermal laser 
4. examine the immediate and long term in vivo effects of non-visible sub-






5. to describe a novel potential biomarker seen in patients with diabetic macular 
edema, and observe in vivo its behavior in respect to changes in macular 







To answer the clinical questions described in the purpose section we performed four 
separate studies. In the following section we present the methods used in each of these 
studies separately. 
All four studies were conducted at the Department of Ophthalmology at the Medical 
University of Vienna. The protocol followed the tenets of the Declaration of Helsinki and 
was registered at www.clinicaltrials.gov (NCT00682240) as well as approved by the 
responsible ethics committee of the Vienna University. In a personal interview, the 
interventional study design, investigations for scientific purposes, and imaging 
procedures were explained in detail to each patient before obtaining informed consent. 
5.1 In vivo examination of retinal changes following panretinal 
photocoagulation 
5.1.1 Patients 
Ten consecutive patients (9 men, 1 woman) assigned to PRP due to proliferative diabetic 
retinopathy were enrolled in a prospective, interventional, and open-labelled trial.  
5.1.2 Examination and documentation 
Before laser treatment, each patient underwent a complete baseline evaluation, including 
slit-lamp examination, ophthalmoscopy, visual acuity testing, fluorescein angiography, 
fundus photography, and SDOCT imaging. Follow-up visits were performed at 1 day and 
1 week after PRP, and at monthly intervals thereafter until month 6. The standardized 
examination procedures were repeated according to protocol at each follow-up visit, 
except fluorescein angiography, which was performed every 3 months. 
5.1.3 Retinal Photocoagulation 
A photocoagulator offering a fully integrated pattern scan laser system designed to treat 
retinal diseases using a single spot or a predetermined pattern array of up to 56 spots was 





laser instrument is capable of delivering high laser powers during short laser exposure 
times (10-20 ms) achieving similar fluences as conventional laser settings. This faster 
laser application allows that a large number of identical spots can be applied by a single 
foot-pedal depression, which allows for constant treatment parameters to be maintained 
during the entire laser procedure at each spot location. For spot size uniformity and 
precise spot placement, identical and reproducible laser power settings were needed to 
obtain reproducible morphologic effects at all spot locations. Photocoagulation was 
performed via irradiation with a frequency doubled neodymium: yttrium-aluminium-
garnet (Nd:YAG) laser diode with a 532-nm wavelength.  
Before the laser procedure, pupillary dilatation was induced by the topical application of 
1% tropicamide (Mydriaticum “Agepha”) and 2.5% phenylephrine hydrochloride eye 
drops. Topical oxybuprocaine 1% (manufactured by the institutional pharmacy) was 
instilled immediately before treatment initiation. Carefully maintaining a safe distance 
from the optic disc of 1 disc diameter, a sufficient number of laser burns were applied, to 
cover the retinal periphery beyond the limits of the upper and lower arcades as close to 
the pars plana as possible.118 A 20-msec burn duration and a 200 μm diameter laser spot 
size were chosen as standard laser settings.44 An Ocular Mainster wide-field contact lens 
(magnification 1.5; Ocular Instruments, Bellevue, WA) was used to focus the laser beam 
on the retina, magnifying the 200 μm diameter laser spot to approximately 300 μm on the 
retinal plane. The laser power (mean, 588 mW; min, 300; max, 1025) was determined 
based on ophthalmoscopic visibility of the treatment spot and adjusted until a distinct 
grey spot was observed clinically. 
5.1.4 Retinal Imaging Using Spectral Domain-Optical Coherence Tomography 
A novel generation SD-OCT was used (Spectralis, Heidelberg Engineering GmbH, 
Heidelberg, Germany), combining high-resolution OCT and fluorescein angiography in 
one instrument, which was useful in our diabetic study population where both diagnostic 
procedures had to be performed. The instrument enables 40.000 A-scans per second. A 
super luminescence diode implemented as the light source in the system radiates an 870-
nm laser beam, which confers improved light penetrating properties to the system 
compared with other systems and provides an axial resolution of 7 μm and a transverse 





of the tissue effects at the level of individual retinal layers and for distinct delineation of 
the thermal damage zone. Another technologic feature relevant to the study purpose and 
superior to other OCT devices is the specific image alignment technique of this device 
for locating, tracking, and constantly aligning retinal locations. Tracking laser 
tomography (TruTrack) enables real-time, simultaneous imaging while tracking eye 
movements. Utilizing this image alignment software, the instrument continuously 
monitors the position of the eye using a beam of light. The tracking system enables the 
scanning of the same exact b-scan multiple times and averaging the images further 
increasing signal to noise ratio. Additionally it allows for the identification of the same 
retinal location throughout each follow-up visit for a precise evaluation of progressive 
changes during the healing response. To reproducibly identify an image location, an area 
closely adjacent to the upper or lower vascular arcades, which was identified by the image 
tracking system, was selected. This location was close to the posterior pole and provided 
a consistent central retinal anatomic structure. 
5.2 In vivo examination of retinal changes following macular grid and focal 
photocoagulation 
5.2.1 Patients 
Thirteen consecutive patients (9 men, 4 women; mean age 58±10 years) with diabetic 
maculopathy showing generalized clinically significant macular edema associated with 
diabetes mellitus type 2 were included in the study. All patients were treatment naïve or 
had not received any treatment for DME at least 3 months before inclusion. 
5.2.2 Examination and documentation 
Color fundus photography and SD-OCT examinations for imaging structural and 
biometric retinal changes secondary to macular grid laser treatment with time and 
biomicroscopy were performed at baseline and day 1. In addition, patients were examined 
using a standardized protocol (ETDRS) for the assessment of best-corrected visual acuity 





5.2.3 Retinal photocoagulation 
In all patients, the PASCAL system was used, which is designed to treat retinal diseases 
using a single spot or a predetermined pattern array of up to 56 spots.117 Procedures before 
the laser procedure were discussed in detail in chapter 5.1.3. 
As recommended for the modified ETDRS grid laser treatment, patients with DME 
received a predetermined grid pattern laser treatment of the edematous perifoveolar 
region in this study setting consisting of 56 laser lesions performed in a homogenous ring 
pattern after energy titration using the PASCAL® Pattern Scan Laser System 
(OptiMedica Corporation, Santa Clara, CA) laser system.25,119 In addition, single 
microaneurysms were coagulated with single laser lesions. In 1 patient, the grid laser 
treatment was performed using a single spot laser treatment. A 10-ms burn duration and 
a 100-μm diameter laser spot size were chosen as standard laser settings, and the treatment 
was performed using an Area Centralis Laser Lens (Volk, Mentor, OH). In all patients, 
the laser power was determined on the basis of ophthalmoscopic visibility of the treatment 
spot and adjusted to a spot of light greyish color observed clinically. 
5.2.4 SD-OCT Imaging 
SD-OCT imaging was performed using the Spectralis OCT (Heidelberg Engineering 
GmbH, Heidelberg, Germany) described in detail in chapter 5.1.4. Retinal thickness 
measurements by SD-OCT were defined as a thickness change in the central millimeter 
of the ETDRS grid. Examination were performed at the same time of the day (late 
morning) based on the possible diurnal fluctuation of the extent of DME.120 
5.3 In vivo morphology of retinal changes following sub-threshold 
panretinal photocoagulation 
5.3.1 Patients 
Ten consecutive patients with retinal or anterior segment neovascularisation due to 
diabetic retinopathy (8 patients) or central retinal vein occlusion (2 patients) were enrolled 





The main inclusion criterion for the study was the need for scatter laser photocoagulation 
because of retinal neovascularisation (neovascularisation on the disc or elsewhere), or 
neovascularisation on the iris caused by type 1 or 2 diabetes mellitus or retinal vascular 
occlusion. Further requirements were no prior laser photocoagulation, no indication for 
intravitreal drug injection and clear optical media. 
5.3.2 Examination and documentation 
Prior to laser treatment, each patient underwent a complete baseline evaluation including 
slit lamp examination, ophthalmoscopy, best corrected ETDRS visual acuity testing, FA, 
color fundus photography, fundus autofluorescence and SD-OCT imaging. Follow-up 
visits were performed at day one, three and seven following laser treatment, and monthly 
intervals thereafter until month 3 with a final visit at 6 month. The standardized 
examination procedures were repeated according to protocol at each follow-up visit, 
except FA, which was performed only at baseline. 
5.3.3 Retinal photocoagulation 
All laser treatments were performed using the PASCAL® Pattern Scan Laser System 
(OptiMedica ® Corporation, Santa Clara, CA, USA), and the Mainster PRP 165 laser lens 
(Ocular Instruments Inc, Bellevue, WA, USA, laser spot magnification 1.96x). A study 
area was selected beside the superior or inferior temporal vessel arcades. After titrating 
the laser power to produce the typical grey- white lesion, the first 2x2 pattern was applied 
in the study area. Afterwards the laser power was decreased to halve the laser irradiation 
fluence (J/cm2) and a second 2x2 pattern was placed adjacent to the first pattern. The 
same process was repeated another two times to produce four group of laser spots from 
threshold to 1/8 fluence. Following the completion of the study zone a standard scatter 
laser therapy was applied in 2 or 3 sessions using standard threshold fluence laser spots. 
5.3.4 SD-OCT Imaging 
SD-OCT evaluation was performed using the Spectralis© OCT system (Heidelberg 
Engineering GmbH, Heidelberg, Germany), that was described in detail in chapter 5.1.4. 
Thirty minutes after laser therapy the patients were imaged using single line scans aligned 





5.4 Hyperreflective foci on OCT in patients with diabetic macular edema 
and their response to macular photocoagulation 
5.4.1 Patients 
Thirteen consecutive patients with CSME due to diabetic retinopathy were enrolled in 
this prospective interventional study performed by a single site (Department of 
Ophthalmology, Medical University of Vienna, Austria).  
Inclusion criteria for the study was type 2 diabetes mellitus, the presence of a clinically 
significant macular edema, no prior laser photocoagulation, no pharmacologic 
intervention within three months prior to inclusion and clear optical media. 
5.4.2 Examination and documentation 
Prior to laser treatment, each patient underwent a complete baseline evaluation including 
slit lamp examination, ophthalmoscopy, BCVA testing, FA, CFP and SD OCT imaging. 
Follow-up visits were performed at day one, week one following laser treatment, and in 
monthly intervals thereafter until month 4. The standardized examination procedures 
were repeated according to protocol at each follow-up visit, except FA, which was 
performed at baseline and every three months. 
5.4.3 Retinal photocoagulation 
Retinal photocoagulation was performed following the modified ETDRS laser 
protocol.118 In case of leakage in FA from microaneurysms, the laser therapy was aimed 
to coagulate the leakage origins. If no leakage source was detectable by FA, a grid pattern 
with barely visible laser burns was applied on the entire edematous area with a 500 micron 
safety distance towards the foveal center. All laser treatments were performed using the 
PASCAL® Pattern Scan Laser System (OptiMedica ® Corporation, Santa Clara, CA, 
USA). 
5.4.4 SD-OCT Imaging 
SD-OCT evaluation was performed using the Spectralis OCT system (Heidelberg 





section 5.1.4. The average thickness value of the central 1mm field of the ETDRS grid 
was used to measure changes in the central retinal thickness (CRT) with time. The thickest 
retinal position (TRP) was also defined at the baseline examination. Using the follow-up 
function, the thickness of the same location was recorded for the follow-up visits as well. 
At baseline one or more regions of interests (ROI) were defined by each patient. These 
ROIs consisted of such areas of the retina, where lipid micro or macro exudates were 
visible. In some cases showing new lipid exudates during follow-up outside of predefined 






The results of the four studies performed are presented below in separate sections. 
6.1 In vivo examination of retinal changes following panretinal 
photocoagulation 
6.1.1 Early Effects of Photocoagulation 
Retinal images for each subject were analysed and revealed comparable results as follows. 
At 1 day after treatment, the focal tissue alteration owing to the applied thermal energy 
was clearly visible in the SD-OCT image (Figure 14.). The morphologic damage was 
characterized by an increased reflectivity and condensation of neurosensory elements 
localizing to the outer retinal layers. The upper margin was located at the level of the 
outer plexiform layer (OPL) and continuous throughout the outer nuclear layer (ONL) 
and the PRL, down to the RPE. The spots seemed to be distinct and were sharply 
delineated toward the adjacent unexposed area, demonstrating an intact layered 
architecture. No transition zone between damaged and undamaged structures was 
observed. Within the well-circumscribed laser burn, retinal striation seemed blurred as 
compared with untreated areas, but still distinguishable. The thickness and contours of 
the single layers remained unmodified; the layers seemed to be continuous, corresponding 
in orientation to the surrounding intact areas. Analysis of the laser spot by each separate 
layer revealed only marginal structural damage of the superficial layers. Manifest 
alterations began within the OPL, which became slightly indistinct and was characterized 
by structural irregularities and blurred borders. The laser tissue interaction extended 
toward the neighbouring ONL, where a pronounced hyperreflectivity of the otherwise 
hyporeflective internal signal was observed, with a sharp demarcation toward the ONL 
of the untreated space between the spots. Within the laser spot, a hardly recognizable 
hyporeflective line adjoining the lower limit of the ONL was interpreted to be the external 
limiting membrane, merging into the PRL. The inner photoreceptor segments seemed to 
be less reflective than their corresponding counterparts in the untreated areas, but the 





signs of laser effects, identified as a reduction in overall reflectivity, together with a 
discrete thinning of all the layers. Light transmission underneath the laser spots was 
decreased. Limited OCT capacity to penetrate to layers below the RPE did not allow for 
an exact interpretation of the choriocapillary anatomy. A lower magnification overview 
clearly highlights the confinement of the laser effects to the outer retinal layers and the 
increased reflectivity, as well as the intact layer organization. 
 
 
Figure 14.: Spectral domain optical coherence tomography (SD-OCT) image of laser 
spots 1 day after photocoagulation. The white circle on the red-free image on the left 
panel indicates the scanned retinal area. Right panel and lower panel: SD-OCT images of 
laser effects: The spots seem to be sharply delineated, uniformly spaced, and of similar 
morphology. Internal layers (inner limiting membrane [ILM], nerve fiber layer [NFL], 
ganglion cell layer [GCL], inner plexiform layer [IPL] and inner nuclear layer [INL]) are 
morphologically unaffected. Obvious structural alterations of the retinal tissue occur 
within the external layers at the OPL and extend through all outer retinal layers toward 
the retinal pigment epithelium [RPE]. ELM: external limiting membrane; ONL: outer 
nuclear layer; OPL: outer plexiform layer; PRL: photoreceptor layer; RPE: retinal 






6.1.2 Healing Response after Photocoagulation 
At 1 week (Figure 15.), the laser spot had contracted in relation to its initial transversal 
as well as longitudinal diameter. The main difference in retinal morphology was the 
involution of the ONL, which was reduced to a thin layer that was most pronounced in 
the central portion of the laser lesion. The resulting narrowing of the ONL led to a 
distortion of the overlying inward layers and the OPL seemed to adhere directly to the 
hyperreflective layer of condensed, amorphous photoreceptor segment remnants. The 
shrinking of the ONL exerted traction through all overlying layers, from the OPL toward 
the ILM, almost causing a depression on the retinal surface. The contracting ONL and 
possibly the condensed PRL induced an outward displacement of retinal strata and as a 
consequence, dissolution of the inner nuclear layer (INL), which was markedly widened 
at the site of the lesion center. Delineated by the slightly hyperreflective OPL, these 
phenomena—ONL loss and INL widening—generated a pattern of “archways,” 
extending from 1 spot to a neighbouring region. Within the lesions at the level of the PRL 
and RPE layer, a secondary tissue response was observed that seemed to be absent in 
earlier follow-up. At the margin of the lesion, and beyond the immediate treatment area, 
a sharply demarcated defect with a complete loss of the photoreceptor segment layer was 
noted. In the lesion center, however, the previous hypodense PRL seemed to be 
condensed and hyperreflective, suggesting that at this location the apoptotic 
photoreceptors were replaced by migrated RPE cells. As described, the atrophy of the 
PRL was not limited to the circumscribed laser burn, but extended in a ring like fashion 
into the surrounding area. Within untreated areas between the laser burns, the PRL and 
the RPE bands were clearly defined, whereas in the photocoagulated tissue it was not 
possible to differentiate between these 2 layers and the PRL and the RPE present as 1 







Figure 15.: Spectral domain optical coherence tomography (SD-OCT) image of laser 
lesions 1 week after treatment. The laser spots were smaller relative to their initial 
diameter and were no longer well-defined, with loss of the previous sharp demarcation. 
Substantial thinning of the outer nuclear layer (ONL) leads to expansion and outward 
displacement of inner retinal layers, but most obviously of the inner nuclear layer (INL), 
which generates the impression of archways connecting neighboring laser burns. The 
photoreceptor layer (PRL) seems to be eliminated, leaving a distinct atrophic zone around 
the spot margins. In the lesion center, the damaged PRL seems to be invaded and partially 
replaced by retinal pigment epithelium (RPE), forming a solid, hyperreflective scar. The 
diameter of the laser scar has reduced to approx.. 250 µm (including the atrophy ring 
(noted erroneously on the published figure))121  
 
During the following weeks (Figure 16.), the hyperdense amorphous material in the lesion 
center underwent progressive resolution and decomposition. The central area of the laser 
spot imposed a circumscribed hyperreflective irregularity with an RPE-like consistency. 
The peripheral defect in the original PRL, however, seemed to be enlarged. The ONL, on 
the other hand, seemed to have recovered partially and could be identified as a separate 
hyporeflective layer between OPL and the damaged PRL. It had not, however, completely 
re-established its original condition. The “archway”-like distortion (INL, ONL) remained 
visible, but was less pronounced than earlier. At 3 and 6 months, the nature of the lesions 





by a focal, amorphous, hyperreflective scar surrounded by a zone of persistent, but not 
further enlarging, defect in the RPE and PRL (Figure 17.). The greatest linear dimension 
of the lesions decreased from the 300 μm seen at day 1 after treatment to approximately 
250 μm at 1 month, and stayed like that until the end of the follow-up period. No scar 
enlargement was observed. 
 
 
Figure 16.: Optical coherence tomography (OCT) image of lesions 1 month after 
treatment. Owing to beginning regeneration of the ONL, the retinal anatomy partially 
normalizes, but the outward distortion and subsequent archway architecture remain 
unchanged. The central hyperplastic scar has contracted, whereas the photoreceptor layer 
(PRL) with inner and outer segments and the external limiting membrane (ELM) is absent 






Figure 17.: Optical coherence tomography (OCT) images at 2 (top) and 3 months 
(bottom) after photocoagulation. The retinal morphology remains remarkably unchanged 
over time: The inner retinal layers from the inner limiting membrane (ILM) to the outer 
plexiform layer (OPL) seem to be intact. The outer nuclear layer (ONL) seems to be 
partially restructured, although thinned. The external limiting membrane (ELM) and 
photoreceptor layer (PRL) remain discontinuous at the lesion margins. The PRL band and 
the RPE layer have condensed and seem smaller, leaving a focal hyperreflective lesion in 
the center of each laser spot.121 
 
6.2 In vivo examination of retinal changes following macular grid and focal 
photocoagulation 
The mean ETDRS visual acuity score for the 13 patients was 74±8. All patients had 
generalized clinically significant macular edema secondary to type 2 diabetes mellitus. 
6.2.1 Morphologic Retinal Changes 
The characteristic changes typically seen in DME, such as cyst formation and diffuse 
swelling in the inner nuclear layer and outer nuclear layer (ONL), were observed in all 





Morphologic changes secondary to the retinal grid photocoagulation were observed on 
day 1. In all patients, each laser lesion was visible as a clear alteration at the level of the 
RPE, the PRL, and to a lesser extent, the ONL. No specific changes of the inner retinal 
layers were observed. The shape of the laser lesions did not show a sagittal alteration 
pattern throughout the outer retinal layers as expected, but rather seemed to have an 
oblique pathway throughout the ONL, changing direction at the level of the external 
limiting membrane (ELM) and proceeding sagittally in the PRL and RPE. 
A representative example of these characteristic effects is shown in Figure 18. Before 
laser treatment (image indicated as baseline), small areas of bleeding were observed in 
the Infrared image (left), and there were large intraretinal cystoid changes in the ONL and 
inner nuclear layer, as well as subretinal fluid beneath the fovea in the OCT image (right). 
One day after laser treatment (indicated as day 1), the laser lesions were slightly visible 
on infrared photography (left) and clearly visible in the corresponding OCT scan (right) 
as diagonal alterations of the ONL, changing their orientation at the border of the ELM. 
The red boxes indicate areas of magnification shown below. All lesions seemed to have 
followed a concentric pathway throughout the outer retinal layers, heading toward the 
center of the grid pattern. This characteristic oblique and concentric laser lesion pattern 
was observed in all patients on day 1. The infrared and OCT findings on day 1 of 3 other 






Figure 18.: Immediate morphologic changes after grid photocoagulation. Morphologic 
findings before (first line) and 1 day after (middle line) laser treatment are shown in 
infrared imaging (left) and OCT (right). The green line in the infrared image indicates the 
position of the scan performed exactly at the same position in both examinations. The red 
boxes indicate the areas (a, b) magnified in the lower line. Laser lesion site (red arrows) 
at the level of the pigment epithelium. The blue lines in the magnifications indicate the 







Figure 19.: Laser lesions 1 day after laser therapy in 3 different patients are shown in 
infrared imaging left and OCT (right). Laser lesion site (red arrows) at the level of the 
pigment epithelium123 
 
Because it was not clear whether these unexpected changes were due to the specific 
PASCAL grid pattern used to perform several laser spots at nearly the same time, in 1 
patient the laser grid treatment was performed with a single laser spot. In this patient as 
well, however, similar changes were observed (Figure 20.) Furthermore, it was not clear 
whether a single laser lesion would cause the same morphologic characteristics. Thus, in 
2 patients the grid laser treatment was performed in 2 steps, first placing 1 single laser 
lesion and analysing its effects on morphology in OCT, and second completing the grid 
photocoagulation as explained above. The results showed that even a single laser lesion 
caused comparable intraretinal changes that did not change in size or position because of 







Figure 20.: Morphologic alterations after a single spot laser treatment in 1 patient. 
Comparable findings to those after grid pattern treatment were detected in infrared 
imaging (left) and OCT (right) before (upper line) and 1 day after laser treatment (lower 
line). Laser lesion site (red arrows) at the level of the pigment epithelium.123 
 
6.2.2 Biometric Retinal Changes 
At baseline, mean central retinal thickness measured in the central millimeter was 
436±124 μm. On day 1, mean CRT was 434±119 μm (P = 0.7). The CRT was decreased 
in 7 patients (range, −3 to −34 μm) and increased in 6 patients (range, 1–40 μm). A 
decrease was observed specifically in 3 patients with subretinal fluid at baseline (−34 μm, 
−17 μm, and −21 μm). 
In those patients with a decrease in CRT on day 1, local thickening was observed in the 
parafoveal area altered by the laser lesions. The scans of 2 patients on day 1 and the 
corresponding thickness profiles automatically generated by the Spectralis software are 
shown in Figure 21A and B. The black curve indicates the actual retinal thickness profile 
of the section shown above. The green area above the curve indicates a decrease, and the 
red area under the curve indicates an increase in the local retinal thickness compared with 





also local swelling at the site of the laser lesions (indicated by the red area in the thickness 
profile). 
 
Figure 21.: Biometric changes 1 day after the laser treatment in 2 patients. The upper 
image shows the OCT scan at day 1; the lower image shows the thickness profile (see 





in the thickness profile. Laser lesion site (red arrows) at the level of the pigment 
epithelium.123 
 
A comparison of the baseline and day 1 findings in the same patient shown in Figure 21B 
is shown in Figure 22. The laser lesions caused measurable local thickening at the level 
of the PRL. In this patient, the distance between the outer border of the RPE and the inner 
border of the inner and outer photoreceptor segment junction was 48 μm at baseline and 
78 μm on day 1. 
 
 
Figure 22.: Local retinal thickening at the laser lesion site. Infrared (left) and OCT 
(middle) findings in the patient from Figure 21B before (upper line) and 1 day after (lower 







6.3 In vivo morphology of retinal changes following sub-threshold 
panretinal photocoagulation 
The mean age of the patients was 60.7 years (28-79 yrs.). 2 patients had type 1 and 6 type 
2 diabetes mellitus. The mean duration of diabetes was 26 years. The duration of 
symptoms in the two patients with central retinal vein occlusion (CRVO) was 7 and 12 
months. At baseline the mean visual acuity of all patients was 0.5 logMAR (SD±0.57), at 
the end of the study 0.68 logMAR (SD±0.62). Two patients developed a vitreous 
hemorrhage and were dropped from the study (both after month 3). The laser settings of 
the titration lesions and the fluences for each patient are shown in Table 1.  
Table 1.: The mean laser parameters of the titration lesions. 

















(ms)     
Fluence 
(J/cm2)  
1 1025 200 20 65 500 200 20 32 
2 650 200 20 41 300 200 20 19 
3 450 200 20 29 225 200 20 14 
4 1300 200 20 83 650 200 20 41 
5 625 200 20 40 325 200 20 21 
6 1150 200 20 73 575 200 20 37 
7 925 200 20 59 500 200 20 32 
8 1900 200 20 120 950 200 20 60 
9 875 200 20 56 400 200 20 26 





200 ±0 20 ±0  63 ±26 
493 
±207 
200 ±0 20 ±0  31 ±13 
  1/4 Fluence 1/8 Fluence 
Patient 
Power 
(mW)   
Spot 
size 




(J/cm2)   
Power 
(mW)    
Spot 
size 
(µm)     
Time 
(ms)      
Fluence 
(J/cm2)      
1 250 200 20 16 125 200 20 8 
2 150 200 20 10       
3 100 200 20 6         
4 325 200 20 21 150 200 20 10 
5 150 200 20 10 100 200 20 6 
6 300 200 20 19       
7 225 200 20 14 100 200 20 6 
8 475 200 20 30       
9 200 200 20 13         










6.3.1 Morphology of laser burns during the follow-up 
6.3.1.1 One hour 
On color fundus photography threshold laser burns were visible as light gray spots with 
blurry contour. Sub-threshold burns with halved fluence became visible in 20% of our 
cases one hour after treatment, and were seen as barely visible light gray spots. Otherwise 
they were not visible. Laser burns with lower fluence were never detectable on CFP. 
Fundus autofluorescence showed barely visible hypofluorescence of the RPE with the 
threshold and halved fluence burns while on infrared (IR) and red free (RF) images they 
were clearly visible. Lower fluences were not detectable with any of the mentioned 
imaging modalities. On SD-OCT threshold laser burns and halved fluence laser burns 
showed similar changes: hyperreflectivity in the outer nuclear layer (ONL), and relative 
hyporeflectivity in the photoreceptor layer (PRL). Irregularities in the retinal pigment 
epithelium (RPE) were also seen in both groups. Although during the laser treatment the 
same spot size setting was used, the halved fluence lesions had a smaller transverse 
diameter (Greatest linear diameter (GLD)) than threshold lesions (234±52 µm vs. 402±42 
µm mean±SD respectively measured on SD-OCT). Laser burns created with quarter or 







Figure 23.: The images of patient 4 during the 6 month follow-up. Left the Infrared 
reflection images (IR) showing the section of the OCT scan in relation to the laser lesions. 
Both the threshold (T) and halved fluence sub-threshold (ST) lesions gain reflectivity 
during the follow-up. The difference in the size of the lesions is clearly visible. SD-OCT 
images of the threshold and halved fluence lesions: at Day 1 the intraretinal vacuole 
formation and subretinal fluid accumulation between the burns is visible that almost 
complete resolves till day 3. The typical archway structure is seen in the threshold lesions 
at month 1 and 6 with a wide PRL defect an RPE loss. The halved fluence burn (the nasal 
one is not well centered on the scan) develops no ONL atrophy, and there is no sign of 
RPE loss around the central RPE/glial proliferation. Nevertheless the PRL only reaches 
the edge of the proliferative tissue, and no reorganization is seen in the central lesion area. 
On fundus autofluorescence the slowly developing central hyperautofluorescence is seen 
with the absence of atrophy ring around the halved fluence lesions. On the right side red 







Figure 24.: IR and separate SD-OCT images of the threshold and sub-threshold laser 
spots accompanied by the FAF and RF images of a patient during the follow-up. At month 
1 and six there is a centripetal reorganization of the PRL and external limiting membrane 
(ELM) in the halved fluence (ST) laser burns.124 
 
6.3.1.2 Day one and three 
On CFP threshold burns became more prominent. In 3 eyes sub-threshold burns were 
barely visible. On FAF both threshold and sub-threshold burns became less 
hyporeflective. On SD-OCT a discrete retinal thickening was observed on day 1 which 
lessened by day 3 and was more prominent at the site of threshold burns. The 
hyperreflectivity of the ONL was unchanged, but intra-retinal “vacuoles” developed 
between the ONL and the PRL in 4 of the eyes. Furthermore sub-retinal fluid (SRF) was 
observed in three eyes between the laser burns. In these cases an irregular thickening of 
the choroid around the laser burns was also seen. (Figure 23. and Figure 25.). All of these 







Figure 25.: SD-OCT image of sub-retinal fluid accumulation and intra-retinal vacuole 
formation 1 day following laser surgery.124 
 
6.3.1.3 Week one 
On CFP and biomicroscopy the acute whitening of the laser burns had begun to diminish 
and the burns were best seen in indirect light. The sub threshold burns became invisible 
at this time. On FAF a distinct hyperfluorescence surrounded by a hypofluorescent ring 
had begun to develop. On SD-OCT the intraretinal fluid (if previously present) together 
with subretinal fluid had disappeared, and the RPE had flattened out. Simultaneously the 
retinal thickness had decreased. The hyperreflectivity of the ONL was replaced with a 
downward shift of the inner layers forming the typical archway figure described in chapter 
6.1.2.121 This archway structure was either not present or only moderately visible in the 
halved fluence burns. 
6.3.1.4 Month one 
On ophthalmoscopy the threshold laser burns had started to pigment, and were 
surrounded by an atrophy ring. The sub threshold burns were either invisible or seen as 
small pigment irregularities. On FAF both threshold and sub threshold burns showed 
hyperfluorescence with surrounding hypofluorescence. The only difference was the size 
of the lesions, the sub-threshold burns being smaller, and often irregular. On SD-OCT in 
the threshold burns the archway configurations had stabilized or in some cases had 
lessened. In the PRL/ RPE layers a central hyperplasia of the RPE was seen surrounded 
by a ring of atrophy (window defects seen on OCT). The PRL was destroyed in the whole 
region of the laser burn. In case of the sub-threshold burns only a minimal thinning of the 





similar hyperplasia in the center of the burn, but the surrounding atrophy was much more 
discrete than for threshold burns. In some cases an impending closure of the defect of the 
PRL was seen as the PRL band together with the external limiting membrane (ELM) 
started to reappear at the edges of the lesions as seen in Figure 24. 
6.3.1.5 Months two through six 
During months 2 through 6 the changes seen on CFP and FAF at month 1 remained 
unchanged, and on SD-OCT the diameter of both threshold and halved fluence burns have 
further shrunk 295±63 µm (73,5% of original GLD), 147±81 µm (61,7% of original GLD) 
respectively. Both changes were statistically significant (p<0.0001). No changes were 
seen in the threshold laser burn morphology, but in 40% of the patients a further 
centripetal reappearance of the PRL and ELM was observed in the sub-threshold laser 
burns, as the PRL band reached and in some cases overlapped the central RPE 
hyperplasia/ glial proliferation (Figure 24.). 
Furthermore as shown in Graph 1. and Graph 2. there was no significant correlation 
between the laser fluence used and the greatest linear diameter of the lesions at month 6 
neither in the threshold nor in the halved fluence lesion groups (r2=0.03 p=0.405 and 







Graph 1.: Scatter plot diagram of the greatest linear diameter (GLD) measured at month 







Graph 2.: Scatter plot diagram of the greatest linear diameter (GLD) measured at month 
6 of the halved fluence laser burns in relation to the fluence used to create them.124 
 
6.4 Hyperreflective foci on OCT in patients with diabetic macular edema 
and their response to macular photocoagulation 
The mean age of the patients was 57 yrs. (range: 44-68 yrs.). All patients (6 male and 7 
female) suffered from type 2 diabetes mellitus. At baseline, the mean retinal thickness in 
the central 1mm ETDRS field was 381µm ± 130µm (mean ±SD). At the end of the follow-
up period, the mean central 1mm retinal thickness was 344µm ± 117µm (mean ±SD). The 
eye tracking system of the Spectralis OCT© enabled the capturing of SD-OCT images 
exactly with the same topography from baseline throughout the subsequent visits allowed 
to determine the thickness change at the thickest retinal position (TRP) (measured at 
baseline) throughout the study. The mean change of the TRP at the end of the four month 





and a final TRP of 480µm±127µm. There was a one ETDRS line visual acuity 
improvement during the follow-up (baseline: 70±12, month four: 75±13). 
At baseline, distinct hyperreflective foci representing early lipid deposits were evenly 
scattered throughout all retinal layers in eyes with DME. During follow-up, the localized 
resorption -therapy response- or the progressive accumulation of intraretinal fluid in 
localized non-responder areas had a major impact on the dynamics and amount of lipid 
foci in these areas. Four characteristic patterns were identified following 






Table 2.: Retinal thickness measurements and distribution patterns of the hyperreflective 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.4.1 Resorption of intraretinal lipids 
A localized decrease in retinal edema was associated with a resolution and a decrease in 
the amount and density of foci (Figure 26. area marked with rectangle). The infrared (A) 
and color fundus images (B) demonstrate no hard exudates, or microaneurysms in the 
scanned area at baseline. In the baseline scan (C), marked hypo-reflectivity and cystoid 
swelling of the outer nuclear layer (ONL) can be observed. Multiple hyperreflective foci 
are present mainly in the ONL, but also in the outer plexiform (OPL) and inner nuclear 
layers (INL). One day after focal laser coagulation (D), an increase in the level of ONL 
thickening and in the number of hyperreflective foci in the ONL has occurred. Three 
months following treatment (E) the outer nuclear layer swelling gradually decreases. 
Hyperreflective microexudates resolved completely In the INL and OPL and partially in 
the ONL. One month later (F – month 4), focal retinal thickening has resolved completely 
together with the disappearance of hyperreflective dots in all retinal layers of the marked 
area.  
 






6.4.2 Condensation of microexudates to clinically visible hard exudates 
In case of decrease in local retinal thickness hyperreflective foci located throughout all 
retinal layers moved toward the apical region of the ONL, and formed condensed larger 
hyperreflective conglomerates. These conglomerates were identified as hard exudates in 
fundus photography. In Figure 27, the 4 month follow-up images of a 47 years old male 
patient are shown. In the fundus photography, a microaneurysm in the nasal inferior 
parafoveal region (center of the marked region) appears clearly visible on the pre-
treatment images (A). During laser treatment, one laser spot was applied to this region to 
occlude the microaneurysm. By color fundus imaging, hard exudates are absent in the 
area of the microaneurysm at the baseline visit. Three month after laser treatment (B), 
focal thickening and appearance of hyperreflective dots at the level of the outer nuclear 
layer is seen in SD-OCT. The infrared image indicates the localization of the scan – 
slightly superior to the microaneurysm. On the color fundus image taken during the same 
visit, hard exudates are visible inferiorly to the microaneurysm, but not superiorly where 
the scan was taken. One month later (C), the focal retinal thickening has resolved, and the 
hyperreflective foci have accumulated and have become confluent in the apical zone of 
the outer nuclear layer involving the outer plexiform and inner nuclear layers. In the color 
photography hard exudates are visible in the scan area as well. A similar but more 
prominent process is seen in Figure 28. In the baseline image (A) circinate hard exudates 
are visible in the color and infrared images. In the corresponding areas (ellipse and right 
side of square) large hyperreflective conglomerates are present in OCT. Four month later 
(B) the hard exudates have partially resolved (encircled area) in OCT the corresponding 
hyperreflective conglomerates became smaller. In the area marked with a square the hard 
exudates flared out, and reached the scan line in a greater extent. In OCT it is clearly 
visible that the center area of the square where at baseline a cystoid swelling of the ONL 
and disseminated small hyperreflective foci were seen has thinned during the follow-up, 
and the ONL is filled with large hyperreflective conglomerates corresponding to the hard 







Figure 27.: Hard exudate formation.125 
 
 
Figure 28.: Formation of hyperreflective conglomerates. (A) Baseline, (B) 4 months 
follow-up.125 
 
6.4.3 Dynamic shifting of microexudates with persisting retinal swelling. 
In the event of stable retinal thickness or further retinal thickening, hyperreflective foci 
were seen in multiple retinal layers throughout the follow-up period. Occasionally some 





foci was seen. In the area marked in Figure 29. retinal thickness slightly increases 
throughout the 4 months associated with a various number and density of hyperreflective 
lesions seen in multiple retinal layers. Overall there is a marked fluctuation in the 
topography of these hyperreflective dots, although there are certain foci that appear to be 
unchanged in respect to location and shape during the entire study. 
 
 
Figure 29.: Dynamic shifting of hyperreflective foci with persisting retinal swelling.125 
 
6.4.4 Dissemination of clinical hard exudates into multiple hyperreflective foci 
In case of continuous retinal swelling in areas where hard exudates were seen at baseline 
the disappearance of the hard exudates were seen on fundus photography. In these cases 
in OCT the dissemination of hyperreflective conglomerates in to multiple hyperreflective 





old female patient showing clinically significant DME with hard exudates at baseline 
examination (A). The lipid exudates (marked area) are clearly visible in both, fundus 
photography and IR image. In the SD-OCT scan, a dense hyperreflective area is seen at 
the level of the outer nuclear/outer plexiform layer consistent with the location of the hard 
exudates ophthalmoscopically. There are several hyperreflective foci in this area spread 
out through all layers of the retina. One month after the laser treatment (B), there is an 
increase in retinal thickening. The hyperreflective area, however, remained unchanged in 
shape and location. The hyperreflective foci in the vicinity of the hard exudate moved 
towards the border of the outer nuclear/outer plexiform layer. Four months after treatment 
(C), there is further increase in the amount of intraretinal fluid, and an accumulation of 
subretinal fluid has occurred. The hard exudate disappeared ophthalmoscopically and in 
the infrared image. In the SD-OCT scan, the large hyperreflective deposit has dissolved 
into two smaller hyperreflective foci, located at INL and ONL. Most of the 
hyperreflective foci previously seen in the outer nuclear layer have disappeared, but there 
are numerous novel hyperreflective foci in the outer plexiform and inner nuclear layers. 
 






Laser therapy has been the gold standard treatment for a number of retinal diseases until 
recent advents in intravitreal pharmacologic therapies.25–29,118 Laser is still an important 
therapeutic procedure, it is performed every day in ophthalmic care centers around the 
world, and will be performed on millions of patients in the future.35,36,113. A novel laser 
improvement called short pule continuous wave lasers were recently introduced. These 
devices deliver laser energy in a ten times shorter time period than in conventional lasers. 
Animal models using this laser delivery method showed reduced collateral damage both 
in the inner retinal layers as well as around the laser spots. In our examinations provide 
evidence, that short pulse laser induces similar laser burn morphology in the human retina 
then in animal models. Our OCT results were very similar to the histological reports of 
Jain et al., that threshold laser lesions with created with 20ms pulse duration did not affect 
the inner retina, but confined in the outer retinal layers.44 Furthermore follow-up 
examinations these lesions showed similar healing response as described by Paulus et al. 
in their animal studies.13 They showed that light-moderate lesions with 20ms pulse 
duration showed focal swelling of the retina an hour after laser, which subsided at day 1, 
and damaged photoreceptors were replaced by hypertrophied glia and hyperpigmented 
RPE cells. Furthermore they described a significant reduction in spot size (40%). In case 
of barely visible and invisible laser lesions (produced with 7ms and 5 ms pulse duration) 
they found initial photoreceptor damage and glial proliferation, which was replaced with 
migrating photoreceptors form neighboring retinal areas, and retinal morphology 
normalized by 4 month post-laser. The results we observed on OCT in the human retina 
are very much in line with these animal model changes. Threshold laser lesions showed 
hyperreflective scars in the level of the RPE and photoreceptors, and the size of the lesions 
did decrease during the follow-up period (although not as much as in the animal models). 
Invisible sub-threshold laser burns showed even less damage in the retina, and with time 
the damage in the photoreceptor layer decreased in many cases resembling the 
photoreceptor shift seen in the aforementioned animal models. 
A major shortcoming of our results, that we can’t draw conclusions about the clinical 





the inner retina (within the nerve fiber laser) in terms of collateral damage in visual field 
and night vision, our study design and cohort size did not allow to examine such effects. 
Muqit et al found favorable PDR regression with short pulse lasers, but more laser burns 
were necessary to control the disease than with conventional lasers.126 The same group 
also examined central and peripheral visual fields after laser therapy and found 
improvements in central visual fields after panretinal laser photocoagulation.127,128 
In the following chapters we will discuss our results, and review current relevant literature 
for each study separately. 
7.1 In vivo examination of retinal changes following panretinal 
photocoagulation 
Diseases of the modern “Western world” lifestyle, mainly diabetes and hypertension, the 
so-called diseases of civilization, affect a growing population worldwide. The 
consequences of these diseases have generated an immense demand for modern, effective 
therapy. In the field of retinal vascular disorders, laser photocoagulation is still considered 
to be a “gold standard” intervention for multiple different indications. Current scientific 
efforts are focused on improving laser therapies with regard to enhancing the therapeutic 
benefit, minimizing the negative side effects, as well as simultaneously improving patient 
and operator comfort and efficiency. The PASCAL laser system used in our study, fulfill 
the requirements for modern treatment, and enable the application of a large number of 
laser spots in 1 second, minimizing patient discomfort and pain by shortening the laser 
pulse duration and optimizing the treatment dose by providing identical laser parameters, 
leading to homogenous effects.117 Because photocoagulation may be associated with 
negative side effects resulting in visual impairment, the aim of recent studies has been to 
determine the optimal treatment parameters required to achieve an adequate therapeutic 
benefit, but reduce unwanted damage.37,47 This issue has been investigated in clinical 
trials comparing “light” or “subthreshold” versus “classic” photocoagulation with varying 
laser energies or laser exposure times.44,129–131 In these studies, “light” photocoagulation 
was superior to classic treatment, showing good therapeutic efficacy and a lower rate of 





retina, layer by layer, is histologic evaluation of the photocoagulated tissue. In previous 
studies, animal models were routinely used to test different laser settings.13,132–134  
Although these animal model studies provided essential basic information, the findings 
have limited applicability because the conditions in the animal models differ from the 
physiology in the diseased human eye, and, most important, preclude a continuous 
follow-up of lesions to examine the characteristic healing response. However, SD-OCT 
is an ideal tool to provide in vivo, high-resolution imaging of retinal tissue with repeated 
evaluation of identical spots over time. The Spectralis OCT system used in our study 
captures high-definition images with exceptional signal to noise ratio. Although the 
resolution is not the same as that of histology, it is sufficient to clearly distinguish the 
components of the retinal layers. Together with the PASCAL laser system, the Spectralis 
OCT offers ideal conditions for evaluating laser tissue damage and the healing response. 
Our study characterized the effect of thermal laser energy on the human retina in vivo, 
observing early primary alterations and subsequent secondary changes. We defined laser 
power settings dependent on the ophthalmologic visibility of the laser burn, visualized as 
a grayish spot. The PASCAL system creates regularly spaced and evenly sized laser spots 
with a similar histologic appearance. Early after treatment (Figure 14.), there was no clear 
change in the inner retinal layers of the coagulated tissue, but structural disorganization 
was observed from the OPL to the RPE. These results are consistent with findings of 
histologic studies done on animal models. After application of laser energy comparable 
to the settings used in our study, alterations mainly appeared in the outer retinal layers 
with detachment of the PRL from the RPE with inward bulking of the neural retina due 
to extensive exudation.13,133 This early localized destruction characterizes the primary 
photocoagulation effect. The SD-OCT images show hyperreflectivity and a granular 
appearance of the ONL, which likely corresponds with the focal necrosis and pyknosis 
observed in histologic preparations. Over time, the cellular swelling recedes and the 
edema is reabsorbed. The lesions shrank continuously and atrophic scarring occurred, 
most impressively at the level of the PRL and RPE (Figure 15.). After 1 month, however, 
the organization of the intraretinal layered pattern had partially recovered and continuous 
SD-OCT imaging revealed an unprecedented intraretinal pattern: owing to 





structures between the laser spots (Figure 16.). Over time, the layer structure partially 
recovered and the misalignment eased. Simultaneously, the atrophic PRL was invaded 
and replaced by tissue, which, on our high-resolution images had the reflectivity of RPE 
cells, resulting in a hyperreflective prominent scar with large pigment clumps. 
Realignment of the intraretinal layers, photoreceptor degradation, and replacement by 
migrating cells constitutes the active secondary healing phase. The present findings are 
consistent with the results of several histologic studies based on animal models.13,131,133–
135 Histologic analyses in several animal models have demonstrated a strong correlation 
between laser power and retinal damage, highlighting the importance of determining laser 
treatment parameters with maximum therapeutic benefit, but minimal collateral 
injury.13,133 These findings, together with the results of several human clinical trials, 
suggest that “light” photocoagulation performed with a short duration continuous laser 
provide the necessary treatment effect on the retinal level. The combination of modern 
laser systems and high-definition OCT techniques providing superior image resolution 
offer the opportunity to monitor the therapeutic effects. 
7.2 In vivo examination of retinal changes following macular grid and focal 
photocoagulation 
The present study examined the immediate morphologic and biometric retinal changes 
secondary to macular grid laser treatment performed with a short duration continuous 
laser in patients with DME using SD-OCT. Characteristic morphologic alteration patterns 
were detectable in the outer retinal layers already at day 1. These alterations were visible 
as oblique hyperreflective changes in the ONL, changing their direction at the level of the 
ELM and continuing sagittally through the PRL and RPE. Clear biometric changes were 
also observed on day 1, indicating an immediate effect, although these changes were not 
statistically significant. 
The characteristic intraretinal morphologic alterations after laser treatment observed in 
this study may be explained by several phenomena. The finding that the photocoagulation 
lesions were not sagittal might have been due to an imaging artefact.136 In several OCT 
devices, scan images are aligned to a certain extent to improve morphologic or biometric 





morphologic retinal details, such as laser lesions. However, this would not explain why 
the laser pathway changes its direction at the level of the ELM. Thus, this explanation 
seems rather unlikely. 
It can also be discussed whether the central grid laser lesions penetrated the ONL in a 
diagonal manner rather than sagittally because of a change in the intraretinal refractive 
index caused by retinal swelling. This could also cause changes in the light and laser light 
pathway through edematous retinal layers. This explanation, however, also seems 
unlikely because the difference between the refractive indices of the vitreous and the 
retina, be it in edematous or physiologic condition, is not remarkably different. 
There may be an immediate thermal photocoagulation effect. The grid itself consists of 
several homogenous single laser spots produced almost at the same time in a ring-shaped 
pattern. This could induce an immediate scarring reaction, leading to a centrifugal 
contraction at the level of the RPE and PRL in the area of the grid pattern. The oblique 
ONL lesions observed in OCT might emerge secondarily because the inner retinal layers 
do not follow this centrifugal outer layer shift. Bruch’s membrane consists of not only 
collagenous but also elastic fibers, possibly inducing a shift of the RPE/PRL complex if 
coagulated. Accordingly, there was no significant transverse shift of the intraretinal 
structures in the inner retinal layers after laser therapy (Figure 18.), corroborating this 
theory. However, in SD OCT a transverse shift of distinct preexisting hyperreflective 
areas within the outer retinal layers (RPE or PRL) could not be identified either. 
Another explanation for these results may be found in the physiologic retinal morphology. 
The shape of the laser lesions complies remarkably with the intraretinal orientation of 
sagittal rods and cones and the subsequent rather oblique inner part of the ONL the 
Henle’s layer. Photocoagulation induces a thermic effect at the level of the RPE and PRL, 
possibly spreading retrogradely into the layers above according to the intraretinal cellular 
architecture. This has not been described in animal studies on histologic retinal changes 
after laser treatment, which again can be explained by differences in retinal architecture 
between, for example, rabbits (not having a foveal retinal excavation) and humans. Only 
in the human or primate fovea, rods and cones are oriented sagittally, and all subsequent 
layers are displaced laterally causing an oblique orientation. Even if the distinct 





cellular orientation in each layer itself could not because of a lack of imaging resolution. 
Thus, according to this theory, these early alterations secondary to laser treatment 
visualize the normal histologic architecture of coagulated photoreceptor complexes, 
beginning at the outer segment of the photoreceptors and ending in the ONL. 
Nevertheless, these explanations are hypothetic and were not examined or authenticated 
in the present study. It does not seem to be a phenomenon typical to only the PASCAL 
laser grid pattern. Comparable results were also observed in a patient treated with a single 
spot photocoagulation (Figure 20.) In addition to the morphologic changes, at day 1 there 
were already clearly measurable biometric changes, although they were not statistically 
significant. It is not clear why there was local thickening in the PRL at the lesion sites 
(Figure 22.). This could be explained by a thermal effect or a transversal RPE/ PRL 
wrinkling according to the centrifugal outer retinal layer shift theory. Studies of how to 
analyze these morphologic changes over time and the impact of these morphologic 
changes on retinal function are in progress. 
7.3 In vivo morphology of retinal changes following sub-threshold 
panretinal photocoagulation 
In our study we demonstrated that laser fluence levels half of the level used to produce 
threshold laser burns produce distinct morphologic changes in the retina as imaged with 
SD-OCT, fundus autofluorescence and color fundus photography. The laser burns created 
with halved fluence showed similar characteristics to threshold burns, but were smaller 
in extent, and importantly showed less collateral damage to the surrounding neuroretina. 
Halved fluence sub-threshold burns had a smaller ring of RPE atrophy –seen as window 
defects surrounding the central pigment proliferation on SD-OCT, and as a 
hypofluorescent ring on fundus autofluorescence. Most importantly there was a tendency 
for photoreceptor layer reorganization (seen as centripetal reappearance of the IS/OS and 
ELM lines in OCT) at the edge of the halved fluence laser spots which was not observed 
in the threshold burns. Lower laser fluence settings did not produce detectable changes in 
the retina at any point during the follow-up. This PRL reorganization may have several 
explanations. It may be caused of sublethal thermal irradiation of the RPE/ PRL at the 





temperature profile during laser treatment which is present even if the laser energy is 
delivered homogeneously throughout the laser lesion.137,138 A different explanation of the 
reappearance of the PRL line in the periphery of the lesions may be shrinkage of the laser 
lesion pulling the PRL towards the glial proliferation in the center of the lesions. 
In their paper Muqit et al. described the morphology of sub-threshold, threshold, and 
supra-threshold laser burns with 20-200 millisecond irradiation times.139 Their results are 
in agreement with our findings, but in our patients we demonstrated similar retinal 
changes with even lower fluence values than Muqit et al. used. Further we could 
demonstrate the photo receptors’ tendency to shift into the direction of the lesion center 
which may be interpreted as a healing response. Inagaki et al also described similar 
morphologic changes following short pulse pattern scanning laser therapy in their paper 
where they compare different laser systems by macular grid laser.140 
Sub-threshold micropulse laser has been examined in several studies in diseases such as 
diabetic macular edema, central serous chorioretinopathy, proliferative diabetic 
retinopathy or branch retinal vein occlusion, and has been found to be effective by some 
authors, whereas other studies found no benefit.52–55,141–143 There is still some debate 
whether micropulse delivery has an advantage over continuous laser.144 
When the Diabetic Retinopathy Study and the Early Treatment Diabetic Retinopathy 
Study first developed the recommended settings for scatter laser photocoagulation in 
patients with proliferative diabetic retinopathy, the aim was to produce “hot” white 
lesions. These standards were revised by several workgroups in order to reduce the 
intensity of the laser burns to the light gray lesions we use today.145 These lesions are still 
clearly visible in the retina during the treatment and afterwards and leave atrophic scars. 
The fact that the gray laser lesions are visible during and after laser surgery means that 
the heat produced by the light absorption in the RPE layer reached the neuroretina through 
thermal diffusion, and was high enough to change its optical quality. This thermal 
diffusion is not just directed toward the neuroretina, but also to the surrounding RPE, and 
choroid causing late laser scar expansion. 
Recent publications suggest that the beneficial effect of laser is not solely due to the 





injured RPE cells.135,146–148 This may mean that the endpoint of our current laser treatment 
strategy is potentially too intense, since destruction of the RPE cells may not be necessary 
to achieve our treatment goals. 
7.4 Hyperreflective foci on OCT in patients with diabetic macular edema 
and their response to macular photocoagulation 
The aim of this study was to examine the morphologic changes of intraretinal lipid 
exudates detected as hyperreflective foci by SD-OCT following retinal photocoagulation. 
SD-OCT images were correlated with color fundus photography and infrared imaging. 
The results show that the localization and movement of lipid foci greatly depend on the 
localized accumulation or resorption of intra-retinal fluid.  
In the event of progressive fluid extravasation with persistent retinal thickening, lipid 
microexudates were constantly present in the retina throughout all layers. The topography 
of these individual microexudates appeared to undergo dynamic changes. On the other 
hand, in the event of localized resorption of intraretinal fluid following laser, the foci 
disappeared first from the inner retinal layers and later from the outer nuclear layer. 
Regarding the relationship of hyperreflective foci and hard exudates two characteristic 
features were identified: In the event of resolution of intraretinal fluid, hyperreflective 
foci formed confluent deposits in the inner part of the outer retinal layers and appeared 
clinically as hard exudates by color fundus photography and IR-imaging. If hard exudates 
were present in an area of persistent retinal thickening, in some cases, a resolution of hard 
exudates was observed by ophthalmoscopy. Independently, hyperreflective foci were still 
detectable by SD-OCT in the treated retinal area. 
Since these hyperreflective foci represent extremely tiny particles in the retina a localized 
change in the amount of intraretinal fluid is enough to induce a change in the topography 
of these foci. This may result in that completely different change patterns are seen at 
different retinal locations of the same patient. 
Since the Early Treatment Diabetic Retinopathy Study it is known that total serum 
cholesterol and LDL fraction cholesterol levels increase the risk of exudative diabetic 





edema have also been reported in subjects who have higher HDL cholesterol or normal 
total cholesterol serum levels.150–156 
Although exudative diabetic maculopathy is currently not an indication for systemic lipid 
lowering therapy, growing number of evidence support that following such a therapy a 
marked reduction of hard exudates occurs in patients with dyslipideamia.151–156 It is also 
known, that with the resolution of macular edema, hard exudates tend to grow in size and 
shift centrally. These subfoveal hard exudates can lead to severe visual loss. If further 
evidence is gathered through multicenter studies regarding the beneficial effect of 
systemic lipid lowering on the presence of retinal hard exudates, it would be most 
informative to evaluate the therapeutic effects using imaging modalities such as SD-OCT 









8.1 In vivo examination of retinal changes following panretinal 
photocoagulation 
Panretinal photocoagulation using a short pulse laser with conventional threshold settings 
resulted in characteristic OCT findings both in the immediate post laser as well as the late 
follow-up period. These findings showed sharp bordered hyperreflective lesions in the 
outer retina at the site of laser irradiation with a transverse dimension comparable to the 
laser spot size setting used. In the reparative phase thinning of the ONL and PRL as well 
as RPE scarring was observed. These finding are very similar to those seen in histological 
animal model studies. We can conclude that the positive characteristics of short pulse 
lasers are also seen in OCTs of the human retina. 
8.2 In vivo examination of retinal changes following macular grid and focal 
photocoagulation 
Characteristic morphologic findings similar to those seen in patients undergoing 
panretinal photocoagulation were seen after macular photocoagulation as well. Disruption 
at the level of the RPE and PRL were evident right after photocoagulation. 
Hyperreflectivity in the ONL showed an oblique orientation with a tilt away from the 
foveal center, very similar to the physiologic orientation of photoreceptor inner segments 
and Henle’s layer. Our theory is that this is evidence that the true thermal laser effect is 
only localized at the RPE/PRL level, and that the changes seen in the ONL are retrograde 
changes to the inner segments of the photoreceptors, and not direct thermal effects. 
8.3 In vivo morphology of retinal changes following sub-threshold 
panretinal photocoagulation 
Sub-threshold laser spots result in definitive changes in the outer retina, but with much 
less retinal pigment epithelium atrophy that enables a reparative mechanism in the 





collateral damage may be possible by reducing the used laser fluence by half. With the 
recent development of pattern scanning laser technology, and fundus tracking imaging, it 
is possible, to deliver complete scatter laser treatments even if the surgeon doesn’t 
actually see the laser lesions during the treatment session since the fundus tracking system 
records where the treatment was done. Recently introduced software algorithms allow the 
physician to easily set the level of sub-threshold fluence after the titration of the threshold 
power, and adjusts laser parameters automatically according to the desired level. This 
way the sub-threshold lesions described in the present paper can be delivered quickly and 
consistently during a panretinal scatter laser session. Limitations of our study are the 
relative low patient number, and that we cannot draw conclusions whether a PRP session 
done with halved fluence lesions is as effective as threshold laser is. Although these 
results are promising, further studies are necessary to assess the efficacy of these sub-
threshold scatter laser treatments, in reducing the risk of developing severe visual acuity 
decrease comparable to standard threshold laser. 
8.4 Hyperreflective foci on OCT in patients with diabetic macular edema 
and their response to macular photocoagulation 
Our recent findings support our previous hypothesis that these hyperreflective foci may 
represent retinal microexudates composed of lipids, lipoproteins or lipid filled 
macrophages and that they are precursors and components of retinal hard exudates. 
Further evidence was supported that retinal hard exudates and microexudates represent a 
dynamic balanced system. The fact that these microexudates are clearly visible in SD-
OCT long before any funduscopically detectable hard exudates appear, can be helpful in 
realistically determining the extent of lipid extravasation due to blood-retinal barrier 
breakdown. This SD-OCT based parameter may be useful in future studies providing new 







In summary our results showed that: 
1)  
a) In vivo morphologic changes after panretinal laser therapy with a short duration 
continuous laser were comparable to result published from histological studies on 
animal models. 
b) Lesions were sharply demarcated, and showed no collateral damage at the edges 
of the lesions 
c) Laser lesions extended to the inner border of the outer nuclear layer, but the inner 
layers of the retina were not affected by direct thermal laser effect. 
2)  
a) During their evolution a loss of PRL and ONL thickness -suggesting 
photoreceptor loss-, as well as RPE atrophy around the scar was observed. 
b) Laser lesions performed by a short duration continuous laser shrank considerably 
during the follow-up period and did not show lesion growth known to happen with 
laser scars of normal duration lasers. 
3)  
a) Laser lesions of macular grid laser were similar in morphology to panretinal 
lesions. The oblique orientation of the lesions in the ONL suggest, that the true 
thermal effect of the laser is only limited to the RPE/PRL layers, and the 
involvement of the ONL is mainly a consequence of retrograde cellular changes. 
4)  
a) Sub-threshold laser lesion created with halved fluence showed similar 
characteristics to threshold lesions, but were smaller in diameter, and showed less 
atrophic RPE changes. 
b) An inward migration of the photoreceptors is possible after sub-threshold laser, 
as the diameter of defects in the PRL layer reduced over time. 
5)  
a) Intraretinal hyperreflective foci are a common finding on OCT in patients with 
diabetic macular edema, and show characteristic changes after laser therapy 





b) Hyperreflective foci in diabetic macular edema may represent microexudates, and 
may serve as precursors of retinal hard exudates. 
c) Hyperreflective foci might be an interesting biomarker in the detection of early 








Kutatási eredményeink alapján összefoglalhatjuk: 
1.  
a. A rövid pulzusú folyamatos lézerrel végzett pánretinális lézerkezelést 
követően észlelhető in vivo elváltozások nagyon hasonlóak voltak a korábbi 
állatmodelleken végzett hisztológiai vizsgálatok eredményeivel. 
b. A lézerhegek élesen demarkálódtak, és a hegek közötti retinán nem látszódtak 
kollaterális károsodások nyomai. 
c. A lézerhegek a külső magvas réteg belső határáig nyúltak, de a retina belső 
rétegei nem mutattak direkt termikus lézer behatás nyomait. 
2.  
a. A lézerhegek fejlődése során fotoreceptor veszteséget sugalló PRL és ONL 
vékonyodást, valamint retinális pigmenthám atrófiát észleltünk. 
b. A rövid pulzusú folyamatos lézerrel végzett lézerhegek jelentős zsugorodáson 
mentek keresztül, és a konvencionális lézerkezelésre jellemző heg 
megnagyobbodás jeleit nem mutatták. 
3.  
a. A makuláris grid lézerkezelés hegei jelentős hasonlóságot mutattak a 
pánretinális lézerkezelésnél látott hegekkel. Az ONL rétegben látható ferde 
heg lefutás a direkt lézer effektus PRL/RPE rétegekre korlátozódását, és az 
ONL réteg inkább másodlagos a fotoreceptorok retrográd érintettségét 
sugallja. 
4.  
a. A felezett energiasűrűséggel létrehozott „sub-threshold” lézerhegek 
morfológiájukban hasonlítottak a „threshold” lézerhegekre, de kisebbek 
voltak, és kevesebb RPE atrófiával jártak. 
b. A „sub-threshold” lézerkezelést követően a PRL rétegben észlelt sérülések 






a. Az intraretinális hyperreflektív pontok gyakori elváltozások a diabéteszes 
makulaödémás betegek OCT felvételein, és lézerkezelést követően az 
intraretinális folyadék csökkenésének vagy gyarapodásának függvényében 
változnak. 
b. Diabéteszes makulaödémában az OCT-n észlelt hyperreflektív pontok 
valószínűleg lipid mikroexudátumok, és a kemény exudátumok előjelei. 
c. A hyperreflektív pontok a diabéteszes makulaödéma és kemény exudátumok 
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